

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Form 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended March 31, 2016

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the transition period from \_\_\_\_ to \_\_\_\_

Commission file number: 333-201719

**BIOTRICITY, INC.**

(Name of Registrant in Its Charter)

**Nevada**

State or Other Jurisdiction of  
Incorporation or Organization)

**47-2548273**

(I.R.S. Employer Identification No.)

**75 International Blvd., Suite 300**

**Toronto, ON M9W 6L9**

(Address of principal executive offices)

(416) 214-3678

(Registrant's Telephone Number, Including Area Code)

Indicate by check whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act).

Large accelerated filer  Accelerated filer

Non-accelerated filer  Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date:

15,876,947 shares of Common Stock, \$0.001 par value at May 16, 2016.

# BIOTRICITY, INC.

## Index

### **Part I – Financial Information**

|   |    |
|---|----|
| <b>Item 1 – Condensed Consolidated Financial Statements</b>   | 3  |
| <b>Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations</b> | 17 |
| <b>Item 3 – Quantitative and Qualitative Disclosures About Market Risk</b>                            | 21 |
| <b>Item 4 - Controls and Procedures</b>   | 21 |
| <b>Part II - Other Information</b>  |    |
| <b>Item 1 - Legal Proceedings</b>   | 23 |
| <b>Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds</b>                           | 23 |
| <b>Item 3 – Defaults Upon Senior Securities</b>   | 23 |
| <b>Item 4 – Mine Safety Disclosures</b>   | 23 |
| <b>Item 5 - Other Information</b>   | 23 |
| <b>Item 6 - Exhibits</b>  | 23 |
| <b>Signatures</b>   | 24 |

## **PART 1**

### **FINANCIAL INFORMATION**

#### **Item 1 – Condensed Consolidated Financial Statements (Unaudited)**

|   |   |
|---|---|
| Condensed Consolidated Balance Sheets at March 31, 2016 and December 31, 2015                         | 4 |
| Condensed Consolidated Statements of Operations for the three months ended<br>March 31, 2016 and 2015 | 5 |
| Condensed Consolidated Statements of Cash Flows for the three months ended<br>March 31, 2016 and 2015 | 6 |
| Notes to Condensed Consolidated Financial Statements  | 7 |

**BIOTRICITY, INC.**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
**As at March 31, 2016 and December 31, 2015 (Unaudited)**  
(Expressed in US dollars)

|  | As at<br>March<br>31, 2016<br>\$ | As at<br>December 31,<br>2015<br>\$ |
|--|----------------------------------|-------------------------------------|
| <b>CURRENT ASSETS</b>  |                                  |                                     |
| Cash   | 53,643                           | 410,601                             |
| Harmonized sales tax recoverable   | 28,656                           | 36,291                              |
| Deposits and other receivables   | 77,186                           | 72,202                              |
| <b>TOTAL ASSETS</b>  | <b>159,485</b>                   | <b>519,094</b>                      |
| <b>LIABILITIES AND STOCKHOLDERS' DEFICIENCY</b>  |                                  |                                     |
| <b>CURRENT LIABILITIES</b>   |                                  |                                     |
| Due to shareholders [Note 5]   | 53,606                           | -                                   |
| Convertible promissory notes [Note 7]  | 102,744                          | -                                   |
| Derivative liabilities [Note 8]  | 75,111                           | -                                   |
| Accounts payable and accrued liabilities [Note 6]  | 463,328                          | 413,273                             |
| <b>Total current liabilities</b>   | <b>694,789</b>                   | <b>413,273</b>                      |
| Convertible promissory notes [Note 7]  | 854,751                          | 783,778                             |
| Derivative liabilities [Note 8]  | 1,179,924                        | 561,220                             |
| <b>TOTAL LIABILITIES</b>   | <b>2,729,464</b>                 | <b>1,758,271</b>                    |
| <b>STOCKHOLDERS' DEFICIENCY</b>  |                                  |                                     |
| Preferred stock, \$0.001 par value, 10,000,000 authorized as at March 31, 2016 (December 31, 2015: 1,000,000), 1 share issued and outstanding as at March 31, 2016 and December 31, 2015, respectively [Note 9]  | 1                                | 1                                   |
| Common stock, \$0.001 par value, 125,000,000 authorized as at March 31, 2016 (December 31, 2015: 100,000,000), 15,876,947 outstanding common shares as at March 31, 2016 and December 31, 2015 and 9,123,031 outstanding exchangeable shares as at March 31, 2016 and December 31, 2015 [Note 9] | 25,000                           | 25,000                              |
| Additional paid in capital   | 7,982,465                        | 7,982,598                           |
| Accumulated other comprehensive loss   | (79,520)                         | (18,002)                            |
| Accumulated deficit  | (10,497,925)                     | (9,228,774)                         |
| <b>Total stockholders' deficiency</b>  | <b>(2,569,979)</b>               | <b>(1,239,177)</b>                  |
| <b>TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY</b>  | <b>159,485</b>                   | <b>519,094</b>                      |

Commitments [Note 11]  
Subsequent events [Note 12]

See accompanying notes to condensed consolidated financial statements

**BIOTRICITY, INC.****CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS  
FOR THE THREE MONTHS ENDED MARCH 31, 2016 AND 2015 (Unaudited)**

(Expressed in US dollars)

|  | Three months<br>ended March<br>31, 2016<br>\$ | Three months<br>ended March<br>31, 2015<br>\$ |
|--|---|---|
| <b>REVENUE</b>   | -   | -   |
| <b>EXPENSES</b>  |   |   |
| General and administrative expenses <i>(Notes 10 and 11)</i>                     | 335,086                                       | 1,439,211                                     |
| Research and development expenses <i>(Note 11)</i>                               | 241,534                                       | 367,194                                       |
| <b>TOTAL OPERATING EXPENSES</b>  | 576,620                                       | 1,806,405                                     |
| Accretion expense <i>(Note 7)</i>  | 73,572  | -   |
| Change in fair value of derivative liabilities <i>(Note 8)</i>                   | 618,959                                       | -   |
| <b>NET LOSS BEFORE INCOME TAXES</b>  | (1,269,151)                                   | (1,806,405)                                   |
| Income taxes   | -   | -   |
| <b>NET LOSS</b>  | (1,269,151)                                   | (1,806,405)                                   |
| Translation adjustment   | (61,518)                                      | (133,930)                                     |
| <b>NET LOSS AND COMPREHENSIVE LOSS</b>   | (1,330,669)                                   | (1,940,335)                                   |
| <b>LOSS PER SHARE, BASIC AND DILUTED</b>   | (0.0508)                                      | (0.0723)                                      |
| <b>WEIGHTED AVERAGE NUMBER OF COMMON AND<br/>EXCHANGEABLE SHARES OUTSTANDING</b> | 24,999,978                                    | 24,999,978                                    |

*See accompanying notes to condensed consolidated financial statements*

**BIOTRICITY, INC.**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**FOR THE THREE MONTHS ENDED MARCH 31, 2016 AND 2015 (Unaudited)**  
(Expressed in US dollars)

|   | Three months<br>ended March 31,<br>2016<br>\$ | Three months<br>ended March 31,<br>2015<br>\$ |
|---|---|---|
| <b>CASH FLOWS FROM OPERATING ACTIVITIES</b>                             |   |   |
| Net loss  | (1,269,151)                                   | (1,806,405)                                   |
| <i>Adjustments to reconcile net loss to net cash used in operations</i> |   |   |
| Stock based compensation  | -   | 1,273,670                                     |
| Accretion expense   | 73,572  | -   |
| Change in fair value of derivative liabilities                          | 618,959                                       | -   |
| <i>Changes in operating assets and liabilities:</i>                     |   |   |
| Harmonized sales tax recoverable  | 9,483   | (4,754)                                       |
| Accounts payable and accrued liabilities                                | 21,656  | (48,644)                                      |
| Deposits and other receivables  | (6,030)                                       | -   |
| <b>Net cash used in operating activities</b>                            | <b>(551,511)</b>                              | <b>(586,133)</b>                              |
| <b>CASH FLOWS FROM FINANCING ACTIVITIES</b>                             |   |   |
| Proceeds from exercise of warrants                                      | -   | 235,379                                       |
| Proceeds from issuance of convertible promissory notes                  | 175,000                                       | -   |
| Due from shareholders   | 50,724  | -   |
| <b>Net cash provided by financing activities</b>                        | <b>225,724</b>                                | <b>235,379</b>                                |
| Net decrease in cash during the period                                  | (325,787)                                     | (350,754)                                     |
| Effect of foreign currency translation                                  | (31,171)                                      | 37,450  |
| Cash, beginning of period   | 410,601                                       | 448,599                                       |
| <b>Cash, end of period</b>  | <b>53,643</b>                                 | <b>135,295</b>                                |

*See accompanying notes to condensed consolidated financial statements*

**BIOTRICITY, INC.**  
**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE THREE MONTHS ENDED MARCH 31, 2016 AND 2015 (Unaudited)**  
(Expressed in US dollars)

**1. NATURE OF OPERATIONS**

Biotricity, Inc. (formerly MetaSolutions, Inc.) (the “Company”) was incorporated under the laws of the State of Nevada on August 29, 2012..

iMedical Innovations Inc. (“iMedical”) was incorporated on July 3, 2014 under the laws of the Province of Ontario, Canada.

Both the Company and iMedical are engaged in research and development activities within the remote monitoring segment of preventative care. They are focused on a realizable healthcare business model that has an existing market and commercialization pathway. As such, its efforts to date have been devoted in building technology that enables access to this market through the development of a tangible product.

On February 2, 2016, the Company entered into an exchange agreement with 1061806 BC LTD. (“Callco”), a British Columbia corporation and wholly owned subsidiary (incorporated on February 2, 2016), 1062024 B.C. LTD., a company existing under the laws of the Province of British Columbia (“Exchangeco”), iMedical Innovation Inc., a company existing under the laws of Canada, and the former shareholders of iMedical (the “Exchange Agreement”), whereby Exchangeco acquired 100% of the outstanding common shares of iMedical, taking into account certain shares pursuant to the Exchange Agreement as further explained in Note 9 to the condensed consolidated financial statements. These subsidiaries were solely used for the issuance of exchangeable shares in the reverse takeover transaction and have no other transactions or balances. After giving effect to this transaction, the Company acquired all of iMedical’s assets and liabilities and commenced operations through iMedical.

As a result of the Share Exchange, iMedical is now a wholly-owned subsidiary of the Company. This transaction has been accounted for as reverse merger. Consequently, the assets and liabilities and the historical operations reflected in the consolidated financial statements for the periods prior to February 2, 2016 are those of iMedical and are recorded at the historical cost basis. After February 2, 2016, the Company’s condensed consolidated financial statements include the assets and liabilities of both iMedical and the Company and the historical operations of both after that date as one entity.

**2. BASIS OF PRESENTATION AND MEASUREMENT**

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and the Securities Exchange Commission (“SEC”) instructions to Form 10-Q and Article 8 of SEC Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements and should be read in conjunction with Biotricity’s audited financial statements for the four months ended December 31, 2015 and year ended August 31, 2015 and notes thereto included in the Form 10-KT filed with the SEC on April 13, 2016 and iMedical’s audited financial statements for the years ended December 31, 2015 and 2014 and notes thereto included in the Form 8-K/A filed with the SEC on April 13, 2016. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of financial position and results of operations for the interim periods presented have been reflected herein. Operating results for the three months ended March 31, 2016, are not necessarily indicative of the results that may be expected for the year ending December 31, 2016.

### 3. GOING CONCERN

The condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred recurring losses from operations and as at March 31, 2016 has an accumulated deficit of \$10,497,925. Management anticipates the Company will attain profitable status and improve its liquidity through continued business development and additional debt or equity investment in the Company. Management is pursuing various sources of financing.

On October 31, 2015, the Company engaged an agent to act as exclusive financial advisor to the Company with respect to assisting the Company in its capital raising efforts as well as assisting the Company in the review of potential financing alternatives available to it and to provide recommendations with respect to the options available to it for meeting its capital needs. Under the engagement agreement, the agent will represent the Company as the sole or lead placement agent, underwriter, book-runner or similar representation in its efforts to obtain financing of up to \$12 million in the form of a private placement, public offering, whether in one or a series of transactions, in a private or public offering of equity, convertible debt or equity, equity linked securities or any other securities.

The Company's continued existence is dependent upon its ability to continue to execute its operating plan and to obtain additional debt or equity financing. There can be no assurance that the necessary debt or equity financing will be available, or will be available on terms acceptable to the Company, in which case the Company may be unable to meet its obligations. Should the Company be unable to realize its assets and discharge its liabilities in the normal course of business, the net realizable value of its assets may be materially less than the amounts recorded in the condensed consolidated financial statements. The condensed consolidated financial statements do not include any adjustments relating to the recoverability of recorded asset amounts that might be necessary should the Company be unable to continue in existence.

### 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

#### Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas involving significant estimates and assumptions include: deferred income tax assets and related valuation allowance, accruals and valuation of warrants and stock options. Actual results could differ from those estimates. These estimates are reviewed periodically, and, as adjustments become necessary, they are reported in earnings in the period in which they become known.

#### Earnings (Loss) Per Share

The Company has adopted the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification ("ASC") Topic 260-10 which provides for calculation of "basic" and "diluted" earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. Diluted earnings per share exclude all potentially dilutive shares if their effect is anti-dilutive. There were no potentially dilutive shares outstanding as at March 31, 2016.



### Fair Value of Financial Instruments

ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

- Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities.
- Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets.
- Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value.

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash and accounts payable. The Company's cash, which is carried at fair value, is classified as a Level 1 financial instrument. The Company’s bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk.

### Recently Issued Accounting Pronouncements

In March 2016, the Company adopted the accounting pronouncement issued by the Financial Accounting Standards Board ("FASB") to update guidance on how companies account for certain aspects of share-based payments to employees. This pronouncement is effective for fiscal years beginning after December 15, 2016, and interim periods within those years, with early adoption permitted. This guidance requires all income tax effects of awards to be recognized in the income statement when the awards vest or are settled and changes the presentation of excess tax benefits on the statement of cash flows. The Company adopted these provisions on a prospective basis. In addition, this pronouncement changes guidance on: (a) accounting for forfeitures of share-based awards and (b) employers’ accounting for an employee’s use of shares to satisfy the employer’s statutory income tax withholding obligation. The adoption of this pronouncement did not have a material impact on the Company’s financial position and/or results of operations.

In February 2016, an accounting pronouncement was issued by the FASB to replace existing lease accounting guidance. This pronouncement is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet for most leases. Expenses associated with leases will continue to be recognized in a manner similar to current accounting guidance. This pronouncement is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted. The adoption is required to be applied on a modified retrospective basis for each prior reporting period presented. The Company has not yet determined the effect that the adoption of this pronouncement may have on our financial position and/or results of operations.

On January 1, 2016, the Company adopted the accounting pronouncement issued by the FASB which eliminates the requirement that an acquirer in a business combination account for measurement-period adjustments retrospectively. Instead, an acquirer will recognize a measurement-period adjustment during the period in which it determines the amount of the adjustment. The adoption of this pronouncement did not have a material impact on the Company's financial position and/or results of operations.

On January 1, 2016, the Company adopted the accounting pronouncement issued by the FASB to update the guidance related to the presentation of debt issuance costs. This guidance requires debt issuance costs, related to a recognized debt liability, be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability rather than being presented as an asset. The Company adopted this pronouncement on a retrospective basis, and the adoption did not have a material impact on the Company financial position and/or results of operations.

In November 2015, an accounting pronouncement was issued by the FASB to simplify the presentation of deferred income taxes within the balance sheet. This pronouncement eliminates the requirement that deferred tax assets and liabilities are presented as current or noncurrent based on the nature of the underlying assets and liabilities. Instead, the pronouncement requires all deferred tax assets and liabilities, including valuation allowances, be classified as noncurrent. This pronouncement is effective for fiscal years beginning after December 15, 2016, with early adoption permitted. The Company intend to adopt this pronouncement on January 1, 2017, and the adoption will not have a material impact on our financial position and/or results of operations.

In May 2014, an accounting pronouncement was issued by the FASB to clarify existing guidance on revenue recognition. This guidance includes the required steps to achieve the core principle that a company should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This pronouncement is effective for fiscal years and interim periods beginning after December 15, 2017, with early adoption permitted. The guidance permits the use of one of two retrospective transition methods. We have not yet selected a transition method nor have the Company determined the effect that the adoption of the pronouncement may have on our financial position and/or results of operations.

## 5. DUE TO SHAREHOLDERS

Amounts due to related parties are unsecured, non-interest bearing and due on demand.

## 6. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

|                        | <b>As at March<br/>31,<br/>2016<br/>\$</b> | <b>As at December<br/>31,<br/>2015<br/>\$</b> |
|------------------------|--|---|
| Trade accounts payable | 447,735                                    | 274,055                                       |
| Accrued liabilities    | 15,593                                     | 139,218                                       |
|                        | <b>463,328</b>                             | <b>413,273</b>                                |

## 7. CONVERTIBLE PROMISSORY NOTES

Pursuant to a term sheet offering of \$2,000,000, the Company during the year ended December 31, 2015 issued convertible promissory notes to various accredited investors amounting to \$1,368,978. These notes have a maturity date of 24 months and carry annual interest rate of 11%. The note holders have the right until any time until the note is fully paid, to convert any outstanding and unpaid principal portion of the note, and accrued interest, into fully paid and non-assessable shares of Common Stock. The note has a conversion price initially set at \$1.78. Upon any future financings completed by the Company, the conversion price will reset to 75% of the future financing pricing. These notes do not contain prepayment penalties upon redemption. These debentures are secured by all of the present and after acquired property of the Company.

However, the Company can force conversion of these notes, if during the term of the agreement, the Company completes a public listing and the Common Share price exceeds the conversion price for at least 20 consecutive trading days. At the closing of the Notes, the Company issued cash (7%) and warrants (7% of the number of Common Shares into which the Notes may be converted) to a brokers. The brokers receive 3% in cash and warrants for those investors in the Presidents List. The warrants have a term of 24 months and a similar reset provision based on future financings.

During March 2016, Biotricity commenced a bridge offering of up to an aggregate of \$1,000,000 of convertible promissory notes to various investors amounting to \$175,000. These notes have a maturity date of 12 months and carry an annual interest rate of 10%. The Bridge Notes principal is paid in cash and interest at 100% average 3 TD VWAP over the last 10 TD plus an embedded warrant at maturity. All of the outstanding principal and accrued interest shall convert (“Forced Conversion”) into units/securities upon the consummation of a Qualified Financing, based upon the lesser of: (i) \$1.65 per units/securities and (ii) the quotient obtained by dividing (x) the balance on the Forced Conversion date multiplied by 1.20 by (y) the actual price per unit/security in the Qualified Financing. Upon the Forced Conversion Date, the Holder shall further be issued Warrants exercisable into a number of shares of Common Stock equal to the number of Conversion Shares (but, in the case of units of securities, the primary equity security or the number of shares of Common Stock underlying the primary security if the primary security is not Common Stock).

The embedded conversion features and reset feature in the notes and broker warrants have been accounted for as a derivative liability based on FASB guidance (refer Note 8).

The movement in convertible promissory notes during the period ended March 31, 2016 is as follows:

|   | \$             |
|---|----------------|
| <b>Accreted value of convertible promissory notes as at December 31, 2015</b> | <b>783,778</b> |
| Face value of convertible promissory notes issued during March 2016           | 175,000        |
| Discount recognised at issuance due to embedded derivatives                   | (74,855)       |
| Accretion expense for Q1 2016   | 73,572         |
| <b>Accreted value of convertible promissory notes as at March 31, 2016</b>    | <b>957,495</b> |

These convertible notes have been presented on balance sheet as follows:

|             | \$             |
|-------------|----------------|
| Current     | 102,744        |
| Non-current | 854,751        |
|             | <b>957,495</b> |

As explained in detail in Note 9, all outstanding convertible promissory notes were exchanged/adjusted pursuant to Exchange Agreement effective February 2, 2016.

## 8. DERIVATIVE LIABILITIES

In connection with the sale of debt or equity instruments, the Company may sell options or warrants to purchase its common stock. In certain circumstances, these options or warrants are classified as derivative liabilities, rather than as equity. Additionally, the debt or equity instruments may contain embedded derivative instruments, such as embedded derivative features which in certain circumstances may be required to be bifurcated from the associated host instrument and accounted for separately as a derivative instrument liability.

The Company's derivative instrument liabilities are re-valued at the end of each reporting period, with changes in the fair value of the derivative liability recorded as charges or credits to income in the period in which the changes occur. For options, warrants and bifurcated embedded derivative features that are accounted for as derivative instrument liabilities, the Company estimates fair value using either quoted market prices of financial instruments with similar characteristics or other valuation techniques. The valuation techniques require assumptions related to the remaining term of the instruments and risk-free rates of return, our current common stock price and expected dividend yield, and the expected volatility of our common stock price over the life of the option.

The derivative liabilities arising from convertible promissory notes/warrants and related issuance of broker warrants are as follows:

|   | <b>Convertible<br/>notes/warrants</b> | <b>Broker<br/>warrants</b> | <b>Total</b>     |
|---|---------------------------------------|----------------------------|------------------|
|   | <b>\$</b>                             | <b>\$</b>                  | <b>\$</b>        |
| <b>Derivative liabilities as at December 31, 2015</b> | <b>480,952</b>                        | <b>80,268</b>              | <b>561,220</b>   |
| Derivative fair value at issuance during March 2016   | 74,855                                | -                          | 74,855           |
| Change in fair value of derivatives                   | 591,044                               | 27,915                     | 618,959          |
| <b>Derivative liabilities as at March 31, 2016</b>    | <b>1,146,851</b>                      | <b>108,183</b>             | <b>1,255,034</b> |

These derivative liabilities have been presented on balance sheet as follows:

|             | <b>\$</b>        |
|-------------|------------------|
| Current     | 75,111           |
| Non-current | 1,179,923        |
|             | <b>1,255,034</b> |

The lattice methodology was used to value the derivative components, using the following assumptions at issuance and period end date of March 31, 2016:

### Assumptions

|                            |               |
|----------------------------|---------------|
| Dividend yield             | 0.00%         |
| Risk-free rate for term    | 0.21% - 0.59% |
| Volatility                 | 100%-105%     |
| Remaining terms (years)    | 1 - 1.5       |
| Stock price (\$ per share) | 2.55 and 2.48 |

The projected annual volatility curve for valuation at issuance and period end was based on the comparable company's annual volatility. The Company used market trade stock prices at issuance and period end date.

## 9. STOCKHOLDERS' DEFICIENCY

### Authorized stock

As at March 31, 2016, the Company is authorized to issue 125,000,000 shares of common stock (\$0.001 par value) and 10,000,000 shares of preferred stock (\$0.001 par value).

As explained below, in contemplation of the acquisition of iMedical on February 2, 2016, the Company's Board of Directors approved the increase in authorized capital stock from 100,000,000 shares of common stock to 125,000,000 shares of common stock, with a par value of \$0.001 per share, and from 1,000,000 shares of preferred stock to 10,000,000 shares of preferred stock, with a par value of \$0.001 per share.

### Issued and outstanding stock

As explained in detail in Note 1 to the condensed consolidated financial statements, with the closing of the Acquisition Transaction on February 2, 2016:

- Biotricity's sole existing director resigned and a new director who is the sole director of the Company was appointed to fill the vacancy;
- Biotricity's sole Chief Executive Officer and sole officer, who beneficially owned 6,500,000 shares of outstanding common stock, resigned from all positions and transferred all of his shares back for cancellation;
- The existing management of the Company were appointed as executive officers; and
- The existing shareholders of the Company entered into a transaction whereby their existing common shares of the Company were exchanged for either (a) a new class of shares that are exchangeable for shares of Biotricity's common stock, or (b) shares of Biotricity's common stock, which (assuming exchange of all such exchangeable shares) would equal in the aggregate a number of shares of Biotricity's common stock that constitute 90% of Biotricity's issued and outstanding shares.

In addition, effective on the closing date of the acquisition transaction:

- Biotricity issued approximately 1.197 shares of its common stock in exchange for each common share of the Company held by the Company shareholders who in general terms, are not residents of Canada (for the purposes of the Income Tax Act (Canada). Accordingly the Company issued 13,376,947 shares;
- Shareholders of the Company who in general terms, are Canadian residents (for the purposes of the Income Tax Act (Canada)) received approximately 1.197 Exchangeable Shares in the capital of Exchangeco in exchange for each common share of the Company held. Accordingly the Company issued 9,123,031 exchangeable shares;
- Each outstanding option to purchase common shares in the Company (whether vested or unvested) was exchanged, without any further action or consideration on the part of the holder of such option, for approximately 1.197 economically equivalent replacement options with an inverse adjustment to the exercise price of the replacement option to reflect the exchange ratio of approximately 1.197:1;
- Each outstanding warrant to purchase common shares in the Company was adjusted, in accordance with the terms thereof, such that it entitles the holder to receive approximately 1.197 shares of the common stock of Biotricity for each Warrant, with an inverse adjustment to the exercise price of the Warrants to reflect the exchange ratio of approximately 1.197:1

- Each outstanding advisor warrant to purchase common shares in the Company was adjusted, in accordance with the terms thereof, such that it entitles the holder to receive approximately 1.197 shares of the common stock of Biotricity for each Advisor Warrant, with an inverse adjustment to the exercise price of the Advisor Warrants to reflect the exchange ratio of approximately 1.197:1; and
- The outstanding 11% secured convertible promissory notes of the Company were adjusted, in accordance with the adjustment provisions thereof, as and from closing, so as to permit the holders to convert (and in some circumstances permit the Company to force the conversion of) the Convertible Debentures into shares of the common stock of Biotricity at a 25% discount to purchase price per share in Biotricity's next offering.

Issuance of preferred stock, common stock, exchangeable shares and cancellation of shares in connection with the reverse takeover transaction as explained above represents recapitalization of capital retroactively adjusting the accounting acquirer's legal capital to reflect the legal capital of the accounting acquiree as at August 31, 2015.

At March 31, 2016 and December 31, 2015 there were 15,876,947 and 9,000,000 shares of common stock issued and outstanding, respectively. There is currently one share of the Special Voting Preferred Stock issued and outstanding held by one holder of record, which is the Trustee in accordance with the terms of the Trust Agreement.

Out of outstanding common stock of 15,876,947 as at March 31, 2016, 750,000 are held in escrow and subject to forfeiture. Of the shares of Common Stock and exchangeable shares issued and outstanding approximately 22,500,000 of such shares are or would be restricted shares under the Securities Act.

### **Stock-based compensation**

On March 30, 2015, iMedical approved Directors, Officers and Employees Stock Option Plan, under which it authorized and issued 3,000,000 options. This plan was established to enable the Company to attract and retain the services of highly qualified and experience directors, officers, employees and consultants and to give such person an interest in the success of the Company.

These options will expire by March 30, 2025. The outstanding options as at March 31, 2016 are as follows:

|                                | No. of options | Exercise Price | Vested options | Unvested options |
|--------------------------------|----------------|----------------|----------------|------------------|
|                                | #              | \$             | #              | #                |
| <b>As at December 31, 2015</b> | <b>167,500</b> | <b>0.0001</b>  | -              | <b>167,500</b>   |
| Adjustment*                    | 33,000         | -              | -              | 33,000           |
| <b>As at March 31, 2016</b>    | <b>200,500</b> | <b>0.0001</b>  | -              | <b>200,500</b>   |

\* As explained above, on February 2, 2016 all outstanding options have been increased by a factor of 1.197.

### **Broker warrants**

The outstanding broker warrants as at March 31, 2016 will expire by May 2018 as detailed below.

|                                | No. of broker<br>warrants | Weighted Average<br>Exercise<br>Price |
|--------------------------------|---------------------------|---------------------------------------|
|                                | #                         | \$                                    |
| <b>As at December 31, 2015</b> | <b>271,742</b>            | <b>1.2000</b>                         |
| Adjustment*                    | 53,503                    | (0.1970)                              |
| <b>As at March 31, 2016</b>    | <b>325,245</b>            | <b>1.0030</b>                         |

\* As explained above, on February 2, 2016 all outstanding broker warrants have been increased by a factor of 1.197.

### **Warrants**

The outstanding warrants as at March 31, 2016 will expire by October 2016 as detailed below.

|                                | No. of<br>warrants | Weighted Average<br>Exercise<br>Price |
|--------------------------------|--------------------|---------------------------------------|
|                                | #                  | \$                                    |
| <b>As at December 31, 2015</b> | <b>380,000</b>     | <b>1.0000</b>                         |
| Adjustment*                    | 74,860             | (0.1970)                              |
| <b>As at March 31, 2016</b>    | <b>454,860</b>     | <b>0.8030</b>                         |

\* As explained above, on February 2, 2016 all outstanding warrants have been increased by a factor of 1.197.

## **10. RELATED PARTY TRANSACTIONS**

The Company's transactions with related parties were carried out on normal commercial terms and in the course of the Company's business.

Other than those disclosed elsewhere in the financial statements, the related party transactions are as follows:

The Company paid consulting charges in cash to its stockholders amounting to \$43,680 and \$60,427 for the three months ended March 31, 2016 and 2015, respectively.

## **11. COMMITMENTS**

- a) On September 14, 2014, the Company finalized an agreement with CardioComm Solutions Inc. ("CardioComm") for the development of a customized software for the ECG. The term of this agreement is later of 5 years or completion of all services from the effective date of agreement, which is September 14, 2014. Pursuant to this agreement, the Company paid CardioComm a non-refundable royalty advance of \$224,775 (CAD 250,000), which was fully expensed during year ended December 31, 2014 as the Company is still under research and development phase. In addition, the Company has committed to pay \$584,415 for design of a Windows Operating System ECG Management Software in accordance with an estimated payment schedules for the work performed. During the three months ended March 31, 2016 and 2015, Company paid \$65,520 and \$72,513, respectively which were expensed and included in research and development expenses.

- b) On July 4, 2014, the Company entered into an operating lease contract for its office premises in Mississauga, Ontario for a one year term. The monthly lease payment was \$3,910 which was increased to \$7,931. The lease agreement also include provisions of Cloud Hosting services at \$2,737 per month and telephone and internet services at \$1,173 per month.
- c) On January 8, 2016, the Company entered into a lease agreement for its office premises in California, USA for a monthly base rent of \$16,530.

## **12. SUBSEQUENT EVENTS**

The Company's management has evaluated subsequent events up to May 16, 2016, the date the financial statements were issued, pursuant to the requirements of ASC 855 and has determined the following material subsequent events:

On May 3, 2016, the Company appointed Mr. David A. Rosa as director to fill the remaining vacancy on the Board of Directors of the Company. In connection with the appointment of Mr. Rosa, the Company authorized the issuance of warrants to purchase 40,000 shares of its common stock, at an exercise price per share of \$2.00, with such other terms and conditions as the officers of the Company deem reasonable and acceptable.

On April 27, 2016, the Company appointed Dr. Norman M. Betts as director to fill one of two vacancies on the Board of Directors. In connection with the appointment of Dr. Betts, the Company authorized the issuance of warrants to purchase 40,000 shares of its common stock, at an exercise price per share of \$2.00, with such other terms and conditions as the officers of the Company deem reasonable and acceptable.

During April, 2016, the Company entered into subscription agreements by and among the Company and the lending parties for the issuance of an aggregate principal amount of \$350,000 unsecured convertible promissory notes pursuant to offering to accredited investors for up to \$1,000,000 as explained in Note 7 to the condensed consolidated financial statements.



## **Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.**

*Except for historical information contained herein, this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contains forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These forward-looking statements were based on various factors and were derived utilizing numerous important assumptions and other important factors that could cause actual results to differ materially from those in the forward-looking statements. Important assumptions and other factors that could cause actual results to differ materially from those in the forward-looking statements, include but are not limited to: (a) any fluctuations in sales and operating results; (b) risks associated with international operations; (c) regulatory, competitive and contractual risks; (d) development risks; (e) the ability to achieve strategic initiatives, including but not limited to the ability to achieve sales growth across the business segments through a combination of enhanced sales force, new products, and customer service; (f) competition in the Company’s existing and potential future product lines of business; (g) the Company’s ability to obtain financing on acceptable terms if and when needed; (h) uncertainty as to the Company’s future profitability; (i) uncertainty as to the future profitability of acquired businesses or product lines; and (j) uncertainty as to any future expansion of the Company. Other factors and assumptions not identified above were also involved in the derivation of these forward-looking statements and the failure of such assumptions to be realized as well as other factors may also cause actual results to differ materially from those projected. The Company assumes no obligation to update these forward looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements. Past results are no guaranty of future performance. You should not place undue reliance on any forward-looking statements, which speak only as of the dates they are made. When used in this Report, the words “believes,” “anticipates,” “expects,” “estimates,” “plans,” “intends,” “will” and similar expressions are intended to identify forward-looking statements.*

This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and footnotes thereto included in this Quarterly Report on Form 10-Q (the “Financial Statements”).

### **Company Overview**

We are a healthcare technology company committed to the development of software and hardware solutions to help the management of chronic health issues. We aim to provide a turnkey, wearable medical cardiac monitoring solution. To achieve this, we are dedicated to continuing our research and development programs, honing our medical-device expertise, increasing our deep knowledge of biometrics, developing both software and hardware components and nurturing a cohesive medical network.

### **Plan of Operation and Recent Corporate Developments**

We were incorporated on August 29, 2012 in the State of Nevada. At the time of our incorporation the name of our company was Metasolutions, Inc. On January 27, 2016, we filed with the Secretary of State of the State of Nevada a Certificate of Amendment to our Articles of Incorporation, effective as of February 1, 2016, whereby, among other things, we changed our name to Biotricity Inc. and increased the authorized number of shares of common stock from 100,000,000 to 125,000,000 and “blank check” preferred stock from 1,000,000 to 10,000,000.

On February 2, 2016 we acquired Biotricity, through our indirect subsidiary Exchangeco and consummated the Acquisition Transaction. Immediately prior to the closing of the Acquisition Transaction, we transferred all of the then-existing business, properties, assets, operations, liabilities and goodwill of the Company, to W270 SA, a Costa Rican corporation, pursuant to the Assignment and Assumption Agreement. Accordingly, as of immediately prior to the closing of the Acquisition Transaction, we had no assets or liabilities.

## **Critical Accounting Policies**

The Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and are expressed in United States Dollars. Significant accounting policies are summarized below:

### Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas involving significant estimates and assumptions include: deferred income tax assets and related valuation allowance, accruals and valuation of warrants and stock options. Actual results could differ from those estimates. These estimates are reviewed periodically, and, as adjustments become necessary, they are reported in earnings in the period in which they become known.

### Earnings (Loss) Per Share

The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 260-10 which provides for calculation of “basic” and “diluted” earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. Diluted earnings per share exclude all potentially dilutive shares if their effect is anti-dilutive. There were no potentially dilutive shares outstanding as at March 31, 2016.

### Fair Value of Financial Instruments

ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

- Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities.
- Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets..
- Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value.

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash and accounts payable. The Company's cash, which is carried at fair value, is classified as a Level 1 financial instrument. The Company’s bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk.

### Recently Issued Accounting Pronouncements

In March 2016, the Company adopted the accounting pronouncement issued by the Financial Accounting Standards Board ("FASB") to update guidance on how companies account for certain aspects of share-based payments to employees. This pronouncement is effective for fiscal years beginning after December 15, 2016, and interim periods within those years, with early adoption permitted. This guidance requires all income tax effects of awards to be recognized in the income statement when the awards vest or are settled and changes the presentation of excess tax benefits on the statement of cash flows. The Company adopted these provisions on a prospective basis. In addition, this pronouncement changes guidance on: (a) accounting for forfeitures of share-based awards and (b) employers' accounting for an employee's use of shares to satisfy the employer's statutory income tax withholding obligation. The adoption of this pronouncement did not have a material impact on the Company's financial position and/or results of operations.

In February 2016, an accounting pronouncement was issued by the FASB to replace existing lease accounting guidance. This pronouncement is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet for most leases. Expenses associated with leases will continue to be recognized in a manner similar to current accounting guidance. This pronouncement is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted. The adoption is required to be applied on a modified retrospective basis for each prior reporting period presented. The Company has not yet determined the effect that the adoption of this pronouncement may have on our financial position and/or results of operations.

On January 1, 2016, the Company adopted the accounting pronouncement issued by the FASB which eliminates the requirement that an acquirer in a business combination account for measurement-period adjustments retrospectively. Instead, an acquirer will recognize a measurement-period adjustment during the period in which it determines the amount of the adjustment. The adoption of this pronouncement did not have a material impact on the Company's financial position and/or results of operations.

On January 1, 2016, the Company adopted the accounting pronouncement issued by the FASB to update the guidance related to the presentation of debt issuance costs. This guidance requires debt issuance costs, related to a recognized debt liability, be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability rather than being presented as an asset. The Company adopted this pronouncement on a retrospective basis, and the adoption did not have a material impact on the Company financial position and/or results of operations.

In November 2015, an accounting pronouncement was issued by the FASB to simplify the presentation of deferred income taxes within the balance sheet. This pronouncement eliminates the requirement that deferred tax assets and liabilities are presented as current or noncurrent based on the nature of the underlying assets and liabilities. Instead, the pronouncement requires all deferred tax assets and liabilities, including valuation allowances, be classified as noncurrent. This pronouncement is effective for fiscal years beginning after December 15, 2016, with early adoption permitted. The Company intend to adopt this pronouncement on January 1, 2017, and the adoption will not have a material impact on our financial position and/or results of operations.

In May 2014, an accounting pronouncement was issued by the FASB to clarify existing guidance on revenue recognition. This guidance includes the required steps to achieve the core principle that a company should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This pronouncement is effective for fiscal years and interim periods beginning after December 15, 2017, with early adoption permitted. The guidance permits the use of one of two retrospective transition methods. We have not yet selected a transition method nor have the Company determined the effect that the adoption of the pronouncement may have on our financial position and/or results of operations.

### **Results of Operations**

From our inception in July 2009 through to March 31, 2016, Biotricity has generated a deficit of \$10,497,925. We expect to incur additional operating losses through the fiscal year ending December 31, 2016 and beyond, principally as a result of our continuing anticipated research and development costs and due to anticipated initial limited sales of the Bioflux, our planned first product. When we approach final stages of the anticipated commercialization of the Bioflux, we will have to devote and expect to continue to devote significant resources in the areas of capital expenditures and research and development costs.

### ***Three Months Ended March 31, 2016 as Compared to Three Months Ended March 31, 2015***

#### *Operating Expenses*

Total operating expenses for the fiscal quarter ended March 31, 2016 were \$576,620 compared to \$1,806,405 for the fiscal quarter ended March 31, 2015, as further described below.

For the fiscal quarter ended March 31, 2016, we incurred research and development expenses of \$241,534, compared to research and development expenses of \$367,194 for the fiscal quarter ended March 31, 2015. The decrease in research and development expenses relates primarily to slow down in research activities during 2016 as management is waiting for the FDA approval.

For the fiscal quarter ended March 31, 2016, we incurred general and administrative expenses of \$335,086, compared to general and administrative expenses of \$1,439,211 for the fiscal quarter ended March 31, 2015. The decrease is mainly due to recording of \$1,273,670 as ESOP expense during Q1 2015 whereas no such expense was recorded during Q1 2016.

Accretion expense and change in fair value of derivative liabilities of \$73,572 and \$618,959, respectively for the year three months ended March 31, 2015 relate to the convertible promissory notes issued during Q4 2015 and Q1 2016.

#### *Net Loss*

Net loss for the fiscal quarter ended March 31, 2016 amounted to \$1,269,151, resulting in a loss per share of \$0.0508, compared to \$1,806,405 for the fiscal quarter ended March 31, 2015, resulting in a loss per share of \$0.0723.

#### *Translation Adjustment*

Translation adjustment for the quarter ended March 31, 2016 was \$61,518 as compared to translation adjustment of \$133,930 for the quarter ended March 31, 2015. This translation adjustment represents loss resulted from the translation of currency in the financial statements from iMedical's functional currency of Canadian dollars to the reporting currency in U.S. dollars.

### **Liquidity and Capital Resources**

We are a development stage company and have not yet realized any revenues from our planned operations. We have working capital deficit of \$535,304 at March 31, 2016, and have incurred a deficit of \$10,497,925 from inception to March 31, 2016. We have funded operations primarily through the issuance of capital stock and other securities.

During the quarter ended March 31, 2016, we raised net cash of \$175,000 through the issuance of convertible promissory notes.

As we proceed with the commercialization of the Bioflux product development we have devoted and expect to continue to devote significant resources in the areas of capital expenditures and research and development costs and operations, marketing and sales expenditures.

We expect to require additional funds to further develop our business plan, including the anticipated commercialization of the Bioflux and Biolife products.. Based on our current operating plans, we will require additional resources to introduce the Bioflux into the Mobile Cardiac Telemetry market and the Biolife device into the consumer market. Since it is impossible to predict with certainty the timing and amount of funds required to launch the Bioflux and Biolife product in any other markets or any of our other proposed products, we anticipate that we will need to raise additional funds through equity or debt offerings or otherwise in order to meet our expected future liquidity requirements. Any such financing that we undertake will likely be dilutive to existing stockholders.

In addition, we expect to also need additional funds to respond to business opportunities and challenges, including our ongoing operating expenses, protecting our intellectual property, developing or acquiring new lines of business and enhancing our operating infrastructure. While we may need to seek additional funding for such purposes, we may not be able to obtain financing on acceptable terms, or at all. In addition, the terms of our financings may be dilutive to, or otherwise adversely affect, holders of our common stock. We may also seek additional funds through arrangements with collaborators or other third parties. We may not be able to negotiate any such arrangements on acceptable terms, if at all. If we are unable to obtain additional funding on a timely basis, we may be required to curtail or terminate some or all of our proposed product lines.

### **Net Cash Used in Operating Activities**

During the quarter ended March 31, 2016, we used cash in operating activities of \$551,511 compared to \$586,133 for the quarter ended March 31, 2015. No significant variation noted.

### **Net Cash Used in Financing Activities**

Net cash provided by financing activities was \$225,724 for the quarter ended March 31, 2016 compared to \$235,379 for the quarter ended March 31, 2015. No significant variation noted.

### **Off-Balance Sheet Arrangements**

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources..

### **Item 3.**

#### **Quantitative and Qualitative Disclosures About Market Risk**

Not applicable.

### **Item 4.**

#### **Controls and Procedures.**

#### **Evaluation of Disclosure Controls and Procedures**

The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company's Exchange Act reports is recorded, processed, summarized and reported within the time communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure based closely on the definition of "disclosure controls and procedures" in Rule 13a-15(e). The Company's disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching the Company's desired disclosure control objectives. In designing periods specified in the SEC's rules and forms, and that such information is accumulated and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. The Company's certifying officer has concluded that the Company's disclosure controls and procedures are effective in reaching that level of assurance.

At the end of the period being reported upon, the Company carried out an evaluation, under the supervision and with the participation of the Company's management, including the Company's Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective.

### **Limitations on the Effectiveness of Controls**

Management has confidence in its internal controls and procedures. The Company's management believes that a control system, no matter how well designed and operated can provide only reasonable assurance and cannot provide absolute assurance that the objectives of the internal control system are met, and no evaluation of internal controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Further, the design of an internal control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitation in all internal control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected.

### **Changes in Internal Controls**

There were no changes in the Company's internal controls over financial reporting that occurred during the transition period ended March 31, 2016 that have materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

Internal control systems, no matter how well designed and operated, have inherent limitations. Therefore, even a system which is determined to be effective cannot provide absolute assurance that all control issues have been detected or prevented. Our systems of internal controls are designed to provide reasonable assurance with respect to financial statement preparation and presentation.

**PART II**  
**OTHER INFORMATION**

**Item 1.**  
**Legal Proceedings.**

None

**Item 1A.**  
**Risk Factors**

Not applicable for smaller reporting companies

**Item 2.**  
**Unregistered Sales of Equity Securities and Use of Proceeds.**

During March 2016, Biotricity commenced a bridge offering of up to an aggregate of \$1,000,000 of convertible promissory notes to various investors amounting to \$175,000. These notes have a maturity date of 12 months and carry an annual interest rate of 10%. The Bridge Notes principal is paid in cash and interest at 100% average 3 TD VWAP over the last 10 TD plus an embedded warrant at maturity. All of the outstanding principal and accrued interest shall convert (“Forced Conversion”) into units/securities upon the consummation of a Qualified Financing, based upon the lesser of: (i) \$1.65 per units/securities and (ii) the quotient obtained by dividing (x) the balance on the Forced Conversion date multiplied by 1.20 by (y) the actual price per unit/security in the Qualified Financing. Upon the Forced Conversion Date, the Holder shall further be issued Warrants exercisable into a number of shares of Common Stock equal to the number of Conversion Shares (but, in the case of units of securities, the primary equity security or the number of shares of Common Stock underlying the primary security if the primary security is not Common Stock).

**Item 3.**  
**Defaults Upon Senior Securities.**

None.

**Item 4.**  
**Mine Safety Disclosures.**

Not applicable.

**Item 5.**  
**Other Information.**

None.

**Item 6. Exhibits**

|              |  |
|--------------|--|
| 31.1         | Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002  |
| 31.2         | Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002  |
| 32.1         | Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 32.2         | Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 101.1        | XBRL Instance.   |
| 101.SCH      | XBRL Taxonomy Extension Schema.  |
| 101.CAL XBRL | Taxonomy Extension Calculation.  |
| 101.DEF XBRL | Taxonomy Extension Definition.   |
| 101.LAB XBRL | Taxonomy Extension Labels.   |
| 101.PRE XBRL | Taxonomy Extension Presentation.   |

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, this 16th day of May 2016.

BIOTRICITY, INC.

By: /s/ Waqaas Al Siddiq

Name: Waqaas Al-Siddiq

Title: Chief Executive Officer

(principal executive and financial officer)



**Certifications of Principal Executive Officer  
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**

I, Waqaas Al-Siddiq, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Biotricity, Inc.;
2. Based upon my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based upon my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:
  - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. Designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrants' board of directors (or persons performing the equivalent functions):
  - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: May 16, 2016

/s/ Waqaas Al Siddiq

Waqaas Al-Siddiq

Chairman and Chief Executive Officer  
(principal executive officer)

Exhibit 31.2  
**Certifications of Principal Financial Officer**  
**Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**

I, Waqaas Al-Siddiq, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Biotricity, Inc.;
2. Based upon my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based upon my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:
  - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. Designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrants' board of directors (or persons performing the equivalent functions):
  - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: May 16, 2016

/s/ Waqaas Al Siddiq  
Waqaas Al-Siddiq  
Chairman and Chief Executive Officer  
(principal financial officer)

**Certification of Principal Executive Officer  
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to  
Section 906 of the Sarbanes-Oxley Act of 2002**

I, Waqaas Al-Siddiq, Chairman and Chief Executive Officer of Biotricity, Inc., hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge, the quarterly report on Form 10-Q for the period ending March 31, 2015 of Biotricity, Inc. (the "Form 10-Q") fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934 and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Biotricity, Inc..

Dated: May 16, 2016

/s/ Waqaas Al Siddiq

Waqaas Al-Siddiq

Chairman and Chief Executive Officer

(principal executive officer)

**Certification of Principal Financial Officer  
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to  
Section 906 of the Sarbanes-Oxley Act of 2002**

I, Waqaas Al-Siddiq, Chairman and Chief Executive Officer of Biotricity, Inc., hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge, the quarterly report on Form 10-Q for the period ending March 31, 2015 of Biotricity, Inc. (the "Form 10-Q") fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934 and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Biotricity, Inc..

Dated: May 16, 2016

/s/ Waqaas Al Siddiq

Waqaas Al-Siddiq

Chairman and Chief Executive Officer

(principal financial officer)

**3 Months Ended****Document and Entity Information****Mar. 31, 2016  
shares****Document and Entity Information:**

|   |                           |
|---|---------------------------|
| <a href="#">Entity Registrant Name</a>                  | BIOTRICITY INC.           |
| <a href="#">Document Type</a>                           | 10-Q                      |
| <a href="#">Document Period End Date</a>                | Mar. 31, 2016             |
| <a href="#">Trading Symbol</a>                          | btcy                      |
| <a href="#">Amendment Flag</a>                          | false                     |
| <a href="#">Entity Central Index Key</a>                | 0001630113                |
| <a href="#">Current Fiscal Year End Date</a>            | --12-31                   |
| <a href="#">Entity Common Stock, Shares Outstanding</a> | 15,876,947                |
| <a href="#">Entity Filer Category</a>                   | Smaller Reporting Company |
| <a href="#">Entity Current Reporting Status</a>         | Yes                       |
| <a href="#">Entity Voluntary Filers</a>                 | No                        |
| <a href="#">Entity Well-known Seasoned Issuer</a>       | No                        |
| <a href="#">Document Fiscal Year Focus</a>              | 2016                      |
| <a href="#">Document Fiscal Period Focus</a>            | Q1                        |

X

**- Definition**

If the value is true, then the document is an amendment to previously- filed/accepted document.

**+ References**

No definition available.

**+ Details**

**Name:** dei\_AmendmentFlag

**Namespace Prefix:** dei\_

**Data Type:** xbrli:booleanItemType

**Balance Type:** na

**Period Type:** duration

X

**- Definition**

End date of current fiscal year in the format - - MM- DD.

**+ References**

No definition available.

**+ Details**

**Name:** dei\_CurrentFiscalYearEndDate

**Namespace Prefix:** dei\_

**Data Type:** xbrli:gMonthDayItemType

**Balance Type:** na

**Period Type:** duration

X

[- Definition](#)

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

[+ References](#)

No definition available.

[+ Details](#)

**Name:** dei\_DocumentFiscalPeriodFocus

**Namespace Prefix:** dei\_

**Data Type:** dei:fiscalPeriodItemType

**Balance Type:** na

**Period Type:** duration

X

[- Definition](#)

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

[+ References](#)

No definition available.

[+ Details](#)

**Name:** dei\_DocumentFiscalYearFocus

**Namespace Prefix:** dei\_

**Data Type:** xbrli:gYearItemType

**Balance Type:** na

**Period Type:** duration

X

[- Definition](#)

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY- MM- DD.

[+ References](#)

No definition available.

[+ Details](#)

**Name:** dei\_DocumentPeriodEndDate

**Namespace Prefix:** dei\_

**Data Type:** xbrli:dateItemType

**Balance Type:** na

**Period Type:** duration

X

[- Definition](#)

The type of document being provided (such as 10- K, 10- Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

[+ References](#)

No definition available.

[+ Details](#)

**Name:** dei\_DocumentType

**Namespace Prefix:** dei\_

**Data Type:** dei:submissionTypeItemType

**Balance Type:** na

**Period Type:** duration

X

- [Definition](#)

A unique 10- digit SEC- issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ [References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC
- Name Regulation 12B
- Number 240
- Section 12b
- Subsection 1

+ [Details](#)

**Name:** dei\_EntityCentralIndexKey

**Namespace Prefix:** dei\_

**Data Type:** dei:centralIndexKeyItemType

**Balance Type:** na

**Period Type:** duration

X

- [Definition](#)

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ [References](#)

No definition available.

+ [Details](#)

**Name:** dei\_EntityCommonStockSharesOutstanding

**Namespace Prefix:** dei\_

**Data Type:** xbrli:sharesItemType

**Balance Type:** na

**Period Type:** instant

X

- [Definition](#)

Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ [References](#)

No definition available.

+ [Details](#)

**Name:** dei\_EntityCurrentReportingStatus

**Namespace Prefix:** dei\_

**Data Type:** dei:yesNoItemType

**Balance Type:** na

**Period Type:** duration

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Nonaccelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

**Name:** dei\_EntityFilerCategory

**Namespace Prefix:** dei\_

**Data Type:** dei:filerCategoryItemType

**Balance Type:** na

**Period Type:** duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC

- Name Regulation 12B

- Number 240

- Section 12b

- Subsection 1

+ Details

**Name:** dei\_EntityRegistrantName

**Namespace Prefix:** dei\_

**Data Type:** xbrli:normalizedStringItemType

**Balance Type:** na

**Period Type:** duration

X

- Definition

Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

+ References

No definition available.

+ Details

**Name:** dei\_EntityVoluntaryFilers

**Namespace Prefix:** dei\_

**Data Type:** dei:yesNoItemType

**Balance Type:** na

**Period Type:** duration

X

- Definition

Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.

+ References

No definition available.



[+ Details](#)

**Name:** dei\_EntityWellKnownSeasonedIssuer

**Namespace Prefix:** dei\_

**Data Type:** dei:yesNoItemType

**Balance Type:** na

**Period Type:** duration

X

[- Definition](#)

Trading symbol of an instrument as listed on an exchange.

[+ References](#)

No definition available.

[+ Details](#)

**Name:** dei\_TradingSymbol

**Namespace Prefix:** dei\_

**Data Type:** xbrli:normalizedStringItemType

**Balance Type:** na

**Period Type:** duration

X

[- References](#)

No definition available.

[+ Details](#)

**Name:** fil\_DocumentAndEntityInformationAbstract

**Namespace Prefix:** fil\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

| <b>Biotricity, Inc. - Condensed Consolidated Balance Sheets -<br/>USD (\$)</b> | <b>Mar. 31, 2016</b> | <b>Dec. 31, 2015</b> |
|--|----------------------|----------------------|
| <b><u>Current Assets:</u></b>  |                      |                      |
| <u>Cash</u>  | \$ 53,643            | \$ 410,601           |
| <u>Harmonized sales tax recoverable</u>  | 28,656               | 36,291               |
| <u>Deposits and other receivables</u>  | 77,186               | 72,202               |
| <u>Total Assets</u>  | 159,485              | \$ 519,094           |
| <b><u>Current Liabilities:</u></b>   |                      |                      |
| <u>Due to shareholders</u>   | [1] 53,606           |                      |
| <u>Convertible promissory notes</u>  | [2] 102,744          |                      |
| <u>Derivative liabilities</u>  | [3] 75,111           |                      |
| <u>Accounts payable and accrued liabilities</u>                                | [4] 463,328          | \$ 413,273           |
| <u>Total current liabilities</u>   | 694,789              | 413,273              |
| <u>Convertible promissory note</u>   | [2] 854,751          | 783,778              |
| <u>Derivative liabilities</u>  | [3] 1,179,924        | 561,220              |
| <b><u>TOTAL LIABILITIES</u></b>  | <b>2,729,464</b>     | <b>1,758,271</b>     |
| <b><u>Stockholders' Deficiency:</u></b>  |                      |                      |
| <u>Preferred stock</u>   | [5] 1                | 1                    |
| <u>Common stock</u>  | [6] 25,000           | 25,000               |
| <u>Additional paid-in capital</u>  | 7,982,465            | 7,982,598            |
| <u>Accumulated other comprehensive loss</u>                                    | (79,520)             | (18,002)             |
| <u>Accumulated deficit</u>   | (10,497,925)         | (9,228,774)          |
| <b><u>TOTAL STOCKHOLDERS' DEFICIENCY</u></b>                                   | <b>(2,569,979)</b>   | <b>(1,239,177)</b>   |
| <b><u>TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY</u></b>                   | <b>\$ 159,485</b>    | <b>\$ 519,094</b>    |

[1] See Note 5

[2] See Note 7

[3] See Note 8

[4] See Note 6

[5] \$0.001 par value; 10,000,000 shares authorized at March 31, 2016 (December 31, 2015: 1,000,000), 1 share issued and outstanding as at March 31, 2016 and December 31, 2015, respectively. See Note 9

[6] \$0.001 par value; 125,000,000 authorized as at March 31, 2016 (December 31, 2015: 100,000,000), 15,876,947 outstanding common shares as at March 31, 2016 and December 31, 2015 and 9,123,031 outstanding exchangeable shares as at March 31, 2016 and December 31, 2015. See Note 9

X

- Definition

Represents the monetary amount of Harmonized sales tax recoverable, as of the indicated date.

+ References

No definition available.

+ Details

**Name:** fil\_HarmonizedSalesTaxRecoverable

**Namespace Prefix:** fil\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** debit

**Period Type:** instant

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.

+ References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 942

- SubTopic 210

- Section S99

- Paragraph 1

- Subparagraph (SX 210.9- 03.15(1),(5))

- URI <http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 944

- SubTopic 210

- Section S99

- Paragraph 1

- Subparagraph (SX 210.7- 03.15)

- URI <http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910>

+ Details

**Name:** us- gaap\_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

X

- Definition

Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non- owner sources, including portion attributable to noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners).

+ References

No definition available.

#### + Details

**Name:** us- gaap\_AccumulatedOtherComprehensiveIncomeLossBeforeTax1

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

#### X

##### - Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid- in capital associated with common and preferred stock. For additional paid- in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid- in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

##### + References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.5- 02.30(a)(1))
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212- 122682>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC
- Name Regulation S- X (SX)
- Number 210
- Section 02
- Paragraph 31
- Article 5

##### + Details

**Name:** us- gaap\_AdditionalPaidInCapital

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

#### X

##### - Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

##### + References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99
- Paragraph 1

- Subparagraph (SX 210.5- 02.18)
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99
- Paragraph 1
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682>

Reference 3: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC
- Name Regulation S- X (SX)
- Number 210
- Section 03
- Paragraph 12
- Article 7

[+ Details](#)

**Name:** us- gaap\_Assets

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** debit

**Period Type:** instant

[X](#)

[- References](#)

No definition available.

[+ Details](#)

**Name:** usgaap\_AssetsCurrentAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

[X](#)

[- Definition](#)

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Glossary Cash
- URI <http://asc.fasb.org/extlink&oid=6506951>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99

- Paragraph 1
  - Subparagraph (SX 210.5- 02.1)
  - URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682>
- + [Details](#)

**Name:** us- gaap\_Cash

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** debit

**Period Type:** instant

X

- [Definition](#)

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ [References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.5- 02.29)
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC
- Name Regulation S- X (SX)
- Number 210
- Section 02
- Paragraph 30
- Article 5

+ [Details](#)

**Name:** us- gaap\_CommonStockValue

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

X

- [Definition](#)

Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.

+ [References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 942
- SubTopic 210
- Section S99

- Paragraph 1
- Subparagraph (SX 210.9- 03.16)
- URI <http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 944
- SubTopic 210
- Section S99
- Paragraph 1
- Subparagraph (SX 210.7- 03.16(a))
- URI <http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910>

Reference 3: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC
- Name Regulation S- X (SX)
- Number 210
- Section 02
- Paragraph 20, 22
- Article 5

[+ Details](#)

**Name:** us- gaap\_ConvertibleNotesPayable

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

**X**

[- Definition](#)

Carrying value as of the balance sheet date of the portion of long- term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.5- 02.20)
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682>

[+ Details](#)

**Name:** usgaap\_ConvertibleNotesPayableCurrent

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

## X

### - Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.

### + References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 20
- Section 55
- Paragraph 10
- URI <http://asc.fasb.org/extlink&oid=51825145&loc=SL20226008-175313>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 825
- SubTopic 10
- Section 50
- Paragraph 15
- URI <http://asc.fasb.org/extlink&oid=49121117&loc=d3e13495-108611>

Reference 3: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 20
- Section 50
- Paragraph 3
- Subparagraph (c)
- URI <http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312>

Reference 4: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 825
- SubTopic 10
- Section 50
- Paragraph 10
- Subparagraph (a)
- URI <http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611>

Reference 5: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 815
- SubTopic 10
- Section 45
- Paragraph 6
- URI <http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958>



Reference 6: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 815
- SubTopic 10
- Section 45
- Paragraph 5
- URI <http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958>

[+ Details](#)

**Name:** us- gaap\_DerivativeLiabilities

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

## X

### [- Definition](#)

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.

### [+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 20
- Section 50
- Paragraph 3
- Subparagraph (c)
- URI <http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Glossary Current Liabilities
- URI <http://asc.fasb.org/extlink&oid=6509677>

Reference 3: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 815
- SubTopic 10
- Section 45
- Paragraph 5
- URI <http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958>

Reference 4: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 815
- SubTopic 10
- Section 45

- Paragraph 6
- URI <http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958>

Reference 5: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 825
- SubTopic 10
- Section 50
- Paragraph 10
- Subparagraph (a)
- URI <http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611>

Reference 6: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 825
- SubTopic 10
- Section 50
- Paragraph 15
- URI <http://asc.fasb.org/extlink&oid=49121117&loc=d3e13495-108611>

[+ Details](#)

**Name:** us- gaap\_DerivativeLiabilitiesCurrent

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

**X**

[- Definition](#)

Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 850
- SubTopic 10
- Section 50
- Paragraph 1
- Subparagraph (d)
- URI <http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 235
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.4- 08.(k)(1))
- URI <http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690>

Reference 3: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.5- 02.19(a))
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212- 122682>

Reference 4: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC
- Name Regulation S- X (SX)
- Number 210
- Section 04
- Paragraph 12
- Subparagraph a(1)
- Article 6

[+ Details](#)

**Name:** us- gaap\_DueToOfficersOrStockholdersCurrent

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

**X**

[- Definition](#)

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.5- 02.19- 26)
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212- 122682>

[+ Details](#)

**Name:** us- gaap\_Liabilities

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

**X**

[- Definition](#)

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.5- 02.32)
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC
- Name Regulation S- X (SX)
- Number 210
- Section 03
- Paragraph 25
- Article 7

[+ Details](#)

**Name:** us- gaap\_LiabilitiesAndStockholdersEquity

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

X

[- Definition](#)

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.5- 02.21)
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682>

[+ Details](#)

**Name:** us- gaap\_LiabilitiesCurrent

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

X

[- References](#)

No definition available.

[+ Details](#)

**Name:** usgaap\_LiabilitiesCurrentAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

## X

### - Definition

The carrying amount of other receivables, net, due within one year of the balance sheet date (or one operating cycle, if longer) from third parties or arising from transactions not separately disclosed.

### + References

No definition available.

### + Details

**Name:** us- gaap\_OtherReceivablesNetCurrent

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** debit

**Period Type:** instant

## X

### - Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

### + References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 505

- SubTopic 10

- Section S99

- Paragraph 1

- Subparagraph (SX 210.3- 04)

- URI <http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 210

- SubTopic 10

- Section S99

- Paragraph 1

- Subparagraph (SX 210.5- 02.28)

- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682>

Reference 3: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC

- Name Regulation S- X (SX)

- Number 210

- Section 02

- Paragraph 29

- Article 5

### + Details

**Name:** us- gaap\_PREFERREDStockValue

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

## X

### - Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

### + References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.5- 02.31(a)(3))
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212- 122682>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC
- Name Regulation S- X (SX)
- Number 210
- Section 04
- Article 3

### + Details

**Name:** us- gaap\_RetainedEarningsAccumulatedDeficit

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

## X

### - Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

### + References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 310
- SubTopic 10
- Section S99
- Paragraph 2
- Subparagraph (SAB TOPIC 4.E)
- URI <http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512- 122707>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.5- 02.29- 31)

- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682>

Reference 3: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC

- Name Staff Accounting Bulletin (SAB)

- Number Topic 4

- Section E

[+ Details](#)

**Name:** us- gaap\_StockholdersEquity

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

[X](#)

[- References](#)

No definition available.

[+ Details](#)

**Name:** usgaap\_StockholdersEquityAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

v3.4.0.3

**Statement of Financial Position - Parenthetical - \$ / shares**    **Mar. 31, 2016**    **Dec. 31, 2015**

**Statement of Financial Position**

|  |             |             |
|--|-------------|-------------|
| <u>Preferred Stock, Par Value</u>          | \$ 0.001    | \$ 0.001    |
| <u>Preferred Stock, Shares Authorized</u>  | 10,000,000  | 1,000,000   |
| <u>Preferred Stock, Shares Issued</u>      | 1           | 1           |
| <u>Preferred Stock, Shares Outstanding</u> | 1           | 1           |
| <u>Common Stock, Par Value</u>             | \$ 0.001    | \$ 0.001    |
| <u>Common Stock, Shares Authorized</u>     | 125,000,000 | 100,000,000 |
| <u>Common Stock, Shares Issued</u>         | 15,876,947  | 9,123,031   |
| <u>Common Stock, Shares Outstanding</u>    | 15,876,947  | 9,123,031   |

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 210

- SubTopic 10

- Section S99

- Paragraph 1

- Subparagraph (SX 210.5- 02.29)

- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC

- Name Regulation S- X (SX)

- Number 210

- Section 02

- Paragraph 30

- Article 5

+ Details

**Name:** usgaap\_CommonStockParOrStatedValuePerShare

**Namespace Prefix:** us- gaap\_

**Data Type:** num:perShareItemType

**Balance Type:** na

**Period Type:** instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 210

- SubTopic 10

- Section S99



- Paragraph 1
- Subparagraph (SX 210.5- 02.29)
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC
- Name Regulation S- X (SX)
- Number 210
- Section 02
- Paragraph 30
- Article 5

[+ Details](#)

**Name:** us- gaap\_CommonStockSharesAuthorized

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:sharesItemType

**Balance Type:** na

**Period Type:** instant

X

[- Definition](#)

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.5- 02.29)
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC
- Name Regulation S- X (SX)
- Number 210
- Section 02
- Paragraph 30
- Article 5

[+ Details](#)

**Name:** us- gaap\_CommonStockSharesIssued

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:sharesItemType

**Balance Type:** na

**Period Type:** instant

X

[- Definition](#)

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

## + References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 505
- SubTopic 10
- Section 50
- Paragraph 2
- URI <http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.5- 02.29)
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682>

Reference 3: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 505
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.3- 04)
- URI <http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770>

Reference 4: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC
- Name Regulation S- X (SX)
- Number 210
- Section 02
- Paragraph 30
- Article 5

## + Details

**Name:** us- gaap\_CommonStockSharesOutstanding

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:sharesItemType

**Balance Type:** na

**Period Type:** instant

## X

### - Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

### + References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210

- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.5- 02.28)
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC
- Name Regulation S- X (SX)
- Number 210
- Section 02
- Paragraph 29
- Article 5

[+ Details](#)

**Name:** us- gaap\_PreferredStockParOrStatedValuePerShare

**Namespace Prefix:** us- gaap\_

**Data Type:** num:perShareItemType

**Balance Type:** na

**Period Type:** instant

X

[- Definition](#)

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.5- 02.28)
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC
- Name Regulation S- X (SX)
- Number 210
- Section 02
- Paragraph 29
- Article 5

[+ Details](#)

**Name:** us- gaap\_PreferredStockSharesAuthorized

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:sharesItemType

**Balance Type:** na

**Period Type:** instant

X

[- Definition](#)

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the

treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

#### + References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.5- 02.28)
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC
- Name Regulation S- X (SX)
- Number 210
- Section 02
- Paragraph 29
- Article 5

#### + Details

**Name:** us- gaap\_PreferredStockSharesIssued

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:sharesItemType

**Balance Type:** na

**Period Type:** instant

## X

#### - Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

#### + References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.5- 02.28)
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC
- Name Regulation S- X (SX)
- Number 210
- Section 02
- Paragraph 29
- Article 5

#### + Details

**Name:** usgaap\_PreferredStockSharesOutstanding

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:sharesItemType

**Balance Type:** na  
**Period Type:** instant

[X](#)

[- References](#)

No definition available.

[+ Details](#)

**Name:** usgaap\_StatementOfFinancialPositionAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

**Biotricity, Inc. - Condensed Consolidated Statements of  
Operations and Comprehensive Loss - USD (\$)**

**3 Months Ended  
Mar. 31, 2016 Mar. 31, 2015**

**Income Statement**

Revenue

**Expenses:**

General and administrative expenses

[1] \$ 335,086 \$ 1,439,211

Research and development expenses

[2] 241,534 367,194

Total Operating Expenses

576,620 \$ 1,806,405

Accretion expense

[3] 73,572

Change in fair value of derivative liabilities

618,959 [4]

Net loss before income taxes

\$ (1,269,151) \$ (1,806,405)

Income taxes

Net loss

\$ (1,269,151) \$ (1,806,405)

Translation adjustment

(61,518) (133,930)

Net loss and comprehensive loss

\$ (1,330,669) \$ (1,940,335)

Loss per share, basic and diluted

\$ (0.0508) \$ (0.0723)

Weighted average common and exchangeable shares  
outstanding

24,999,978 24,999,978

[1] See Notes 10 and 11

[2] See Note 11

[3] See Note 7

[4] See Note 8

X

- Definition

Harmonized sales tax recoverable.

+ References

No definition available.

+ Details

**Name:** fil\_ChangeInFairValueOfDerivativeLiabilities

**Namespace Prefix:** fil\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** debit

**Period Type:** duration

X

- Definition

Net loss before income taxes.

+ References

No definition available.

+ Details

**Name:** fil\_NetLossAndComprehensiveLoss

**Namespace Prefix:** fil\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** debit  
**Period Type:** duration

X

- Definition

Change in fair value of derivative liabilities.

+ References

No definition available.

+ Details

**Name:** fil\_NetLossBeforeIncomeTaxes

**Namespace Prefix:** fil\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** debit

**Period Type:** duration

X

- Definition

Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.

+ References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 410

- SubTopic 20

- Section 45

- Paragraph 1

- URI <http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 420

- SubTopic 10

- Section 35

- Paragraph 4

- URI <http://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866>

+ Details

**Name:** us- gaap\_AccretionExpense

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** debit

**Period Type:** duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

[+ References](#)

No definition available.

[+ Details](#)

**Name:** us- gaap\_EarningsPerShareBasicAndDiluted

**Namespace Prefix:** us- gaap\_

**Data Type:** num:perShareItemType

**Balance Type:** na

**Period Type:** duration

**X**

[- Definition](#)

Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 830

- SubTopic 20

- Section 45

- Paragraph 1

- URI <http://asc.fasb.org/extlink&oid=6450189&loc=d3e30690-110894>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 830

- SubTopic 20

- Section 50

- Paragraph 1

- URI <http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895>

Reference 3: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 830

- SubTopic 20

- Section 45

- Paragraph 2

- URI <http://asc.fasb.org/extlink&oid=6450189&loc=d3e30700-110894>

[+ Details](#)

**Name:** us- gaap\_ForeignCurrencyTransactionLossBeforeTax

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** debit

**Period Type:** duration

**X**

[- Definition](#)

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

[+ References](#)



Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 225
- SubTopic 10
- Section S99
- Paragraph 2
- Subparagraph (SX 210.5- 03.4)
- URI <http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235- 122688>

[+ Details](#)

**Name:** usgaap\_GeneralAndAdministrativeExpense

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** debit

**Period Type:** duration

X

[- References](#)

No definition available.

[+ Details](#)

**Name:** usgaap\_IncomeStatementAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

X

[- Definition](#)

The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 230
- SubTopic 10
- Section 50
- Paragraph 2
- URI <http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297- 108586>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 230
- SubTopic 10
- Section 45
- Paragraph 25
- Subparagraph (f)
- URI <http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536- 108585>

[+ Details](#)

**Name:** us- gaap\_IncomeTaxesPaid

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

**Name:** us- gaap\_OperatingExpenses

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** debit

**Period Type:** duration

X

- References

No definition available.

+ Details

**Name:** usgaap\_OtherExpensesAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

X

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 810

- SubTopic 10

- Section 45

- Paragraph 19

- URI <http://asc.fasb.org/extlink&oid=51664549&loc=SL4569616-111683>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 810

- SubTopic 10

- Section 55

- Paragraph 4K

- URI <http://asc.fasb.org/extlink&oid=35736750&loc=SL4591552-111686>

Reference 3: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 810

- SubTopic 10
- Section 50
- Paragraph 1A
- Subparagraph (a),(c)
- URI <http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684>

Reference 4: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 810
- SubTopic 10
- Section 55
- Paragraph 4J
- URI <http://asc.fasb.org/extlink&oid=35736750&loc=SL4591551-111686>

[+ Details](#)

**Name:** us- gaap\_ProfitLoss

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** duration

X

[- Definition](#)

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in- process projects deemed to have no alternative future use.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 730
- SubTopic 10
- Section 50
- Paragraph 1
- URI <http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 985
- SubTopic 20
- Section 50
- Paragraph 1
- URI <http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756>

[+ Details](#)

**Name:** usgaap\_ResearchAndDevelopmentExpense

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** debit  
**Period Type:** duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 225
- SubTopic 10
- Section S99
- Paragraph 2
- Subparagraph (SX 210.5- 03.1)
- URI <http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235- 122688>

+ Details

**Name:** us- gaap\_Revenues

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** duration

X

- Definition

Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).

+ References

No definition available.

+ Details

**Name:** us- gaap\_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:sharesItemType

**Balance Type:** na

**Period Type:** duration

v3.4.0.3

| <b>Biotricity, Inc. - Condensed Consolidated Statements of Cash Flows - USD (\$)</b> | <b>3 Months Ended</b> |                      |
|--|-----------------------|----------------------|
|  | <b>Mar. 31, 2016</b>  | <b>Mar. 31, 2015</b> |
| <b><u>Cash flow from operating activities:</u></b>                                   |                       |                      |
| <u>Net loss</u>  | \$ (1,269,151)        | \$ (1,806,405)       |
| <b><u>Adjustments to reconcile net loss to net cash used in operations</u></b>       |                       |                      |
| <u>Stock based compensation</u>  |                       | \$ 1,273,670         |
| <u>Accretion expense</u>   | [1] 73,572            |                      |
| <u>Change in fair value of derivative liabilities</u>                                | 618,959 [2]           |                      |
| <b><u>Changes in operating assets and liabilities:</u></b>                           |                       |                      |
| <u>Harmonized sales tax recoverable</u>  | 9,483                 | \$ (4,754)           |
| <u>Accounts payable and accrued liabilities</u>                                      | 21,656                | (48,644)             |
| <u>Deposits and other receivables</u>  | (6,030)               |                      |
| <u>Net Cash used in operating activities</u>   | (551,511)             | (586,133)            |
| <b><u>Cash flows from financing activities:</u></b>                                  |                       |                      |
| <u>Proceeds from exercise of warrants</u>  |                       | 235,379              |
| <u>Proceeds from issuance of convertible promissory notes</u>                        | 175,000               |                      |
| <u>Due from shareholders</u>   | 50,724                |                      |
| <u>Net Cash provided by financing activities</u>                                     | 225,724               | 235,379              |
| <u>Net decrease in cash during the period</u>  | (325,787)             | (350,754)            |
| <u>Effect of foreign currency translation</u>  | (31,171)              | 37,450               |
| <u>Cash, beginning of period</u>   | 410,601               | 448,599              |
| <u>Cash, end of period</u>   | \$ 53,643             | \$ 135,295           |

[1] See Note 7

[2] See Note 8

X

- Definition

Harmonized sales tax recoverable.

+ References

No definition available.

+ Details

**Name:** fil\_ChangeInFairValueOfDerivativeLiabilities

**Namespace Prefix:** fil\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** debit

**Period Type:** duration

X

- Definition

Proceeds from issuance of convertible promissory notes.

+ References

No definition available.

[+ Details](#)

**Name:** fil\_DueFromShareholders  
**Namespace Prefix:** fil\_  
**Data Type:** xbrli:monetaryItemType  
**Balance Type:** debit  
**Period Type:** duration

X

[- Definition](#)

Due from shareholders.

[+ References](#)

No definition available.

[+ Details](#)

**Name:** fil\_EffectOfForeignCurrencyTranslation  
**Namespace Prefix:** fil\_  
**Data Type:** xbrli:monetaryItemType  
**Balance Type:** debit  
**Period Type:** duration

X

[- Definition](#)

Net loss and comprehensive loss.

[+ References](#)

No definition available.

[+ Details](#)

**Name:** fil\_HarmonizedSalesTaxRecoverable1  
**Namespace Prefix:** fil\_  
**Data Type:** xbrli:monetaryItemType  
**Balance Type:** debit  
**Period Type:** duration

X

[- Definition](#)

Harmonized sales tax recoverable.

[+ References](#)

No definition available.

[+ Details](#)

**Name:** fil\_ProceedsFromIssuanceOfConvertiblePromissoryNotes  
**Namespace Prefix:** fil\_  
**Data Type:** xbrli:monetaryItemType  
**Balance Type:** debit  
**Period Type:** duration

X

[- Definition](#)

Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 410
- SubTopic 20

- Section 45
- Paragraph 1
- URI <http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 420
- SubTopic 10
- Section 35
- Paragraph 4
- URI <http://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866>

[+ Details](#)

**Name:** us- gaap\_AccretionExpense

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** debit

**Period Type:** duration

X

[- References](#)

No definition available.

[+ Details](#)

**Name:** usgaap\_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

X

[- Definition](#)

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short- term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Glossary Cash
- URI <http://asc.fasb.org/extlink&oid=6506951>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section 45
- Paragraph 1
- Subparagraph (a)
- URI <http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765>

Reference 3: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 230
- SubTopic 10
- Section 45
- Paragraph 4
- URI <http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585>

Reference 4: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Glossary Cash Equivalents
- URI <http://asc.fasb.org/extlink&oid=6507016>

Reference 5: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.5- 02.1)
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682>

[+ Details](#)

**Name:** usgaap\_CashAndCashEquivalentsAtCarryingValue

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** debit

**Period Type:** instant

X

[- Definition](#)

Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 830
- SubTopic 230
- Section 45
- Paragraph 1
- URI <http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906>

[+ Details](#)

**Name:** us- gaap\_CashPeriodIncreaseDecrease

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** debit

**Period Type:** duration



X

- Definition

The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.

+ References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 230
- SubTopic 10
- Section 45
- Paragraph 28
- Subparagraph (a)
- URI <http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585>

+ Details

**Name:** us- gaap\_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** debit

**Period Type:** duration

X

- References

No definition available.

+ Details

**Name:** usgaap\_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

X

- Definition

The increase (decrease) during the reporting period in other amounts due to the reporting entity, which are not otherwise defined in the taxonomy.

+ References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 230
- SubTopic 10
- Section 45
- Paragraph 28
- Subparagraph (a)
- URI <http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585>

+ Details

**Name:** us- gaap\_IncreaseDecreaseInOtherReceivables

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** duration

## X

### - Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long- term credit.

### + References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 230
- SubTopic 10
- Section 45
- Paragraph 24
- URI <http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 230
- SubTopic 10
- Section 45
- Paragraph 26
- URI <http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585>

### + Details

**Name:** usgaap\_NetCashProvidedByUsedInFinancingActivities

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** debit

**Period Type:** duration

## X

### - References

No definition available.

### + Details

**Name:** usgaap\_NetCashProvidedByUsedInFinancingActivitiesAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

## X

### - Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

### + References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 230
- SubTopic 10
- Section 45
- Paragraph 24

- URI <http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 230
- SubTopic 10
- Section 45
- Paragraph 28
- URI <http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585>

Reference 3: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 230
- SubTopic 10
- Section 45
- Paragraph 25
- URI <http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585>

[+ Details](#)

**Name:** us- gaap\_NetCashProvidedByUsedInOperatingActivities

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** na

**Period Type:** duration

X

[- References](#)

No definition available.

[+ Details](#)

**Name:** usgaap\_NetCashProvidedByUsedInOperatingActivitiesAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

X

[- Definition](#)

The cash inflow associated with the amount received from holders exercising their stock warrants.

[+ References](#)

No definition available.

[+ Details](#)

**Name:** us- gaap\_ProceedsFromWarrantExercises

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** debit

**Period Type:** duration

X

[- Definition](#)

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 810
- SubTopic 10
- Section 45
- Paragraph 19
- URI <http://asc.fasb.org/extlink&oid=51664549&loc=SL4569616-111683>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 810
- SubTopic 10
- Section 55
- Paragraph 4K
- URI <http://asc.fasb.org/extlink&oid=35736750&loc=SL4591552-111686>

Reference 3: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 810
- SubTopic 10
- Section 50
- Paragraph 1A
- Subparagraph (a),(c)
- URI <http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684>

Reference 4: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 810
- SubTopic 10
- Section 55
- Paragraph 4J
- URI <http://asc.fasb.org/extlink&oid=35736750&loc=SL4591551-111686>

[+ Details](#)

**Name:** us- gaap\_ProfitLoss

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** duration

**X**

[- Definition](#)

The aggregate amount of noncash, equity- based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 230

- SubTopic 10
- Section 45
- Paragraph 28
- Subparagraph (a)
- URI <http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585>

[+ Details](#)

**Name:** us- gaap\_ShareBasedCompensation

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** debit

**Period Type:** duration

## 1. Nature of Operations

**3 Months Ended  
Mar. 31, 2016**

### Notes

#### 1. Nature of Operations

#### **1. NATURE OF OPERATIONS**

Biotricity, Inc. (formerly MetaSolutions, Inc.) (the “Company”) was incorporated under the laws of the State of Nevada on August 29, 2012.

iMedical Innovations Inc. (“iMedical”) was incorporated on July 3, 2014 under the laws of the Province of Ontario, Canada.

Both the Company and iMedical are engaged in research and development activities within the remote monitoring segment of preventative care. They are focused on a realizable healthcare business model that has an existing market and commercialization pathway. As such, its efforts to date have been devoted in building technology that enables access to this market through the development of a tangible product.

On February 2, 2016, the Company entered into an exchange agreement with 1061806 BC LTD. (“Callco”), a British Columbia corporation and wholly owned subsidiary (incorporated on February 2, 2016), 1062024 B.C. LTD., a company existing under the laws of the Province of British Columbia (“Exchangeco”), iMedical Innovation Inc., a company existing under the laws of Canada, and the former shareholders of iMedical (the “Exchange Agreement”), whereby Exchangeco acquired 100% of the outstanding common shares of iMedical, taking into account certain shares pursuant to the Exchange Agreement as further explained in Note 9 to the condensed consolidated financial statements. These subsidiaries were solely used for the issuance of exchangeable shares in the reverse takeover transaction and have no other transactions or balances. After giving effect to this transaction, the Company acquired all of iMedical’s assets and liabilities and commenced operations through iMedical.

As a result of the Share Exchange, iMedical is now a wholly-owned subsidiary of the Company. This transaction has been accounted for as reverse merger. Consequently, the assets and liabilities and the historical operations reflected in the consolidated financial statements for the periods prior to February 2, 2016 are those of iMedical and are recorded at the historical cost basis. After February 2, 2016, the Company’s condensed consolidated financial statements include the assets and liabilities of both iMedical and the Company and the historical operations of both after that date as one entity.

X

- References

No definition available.

+ Details

**Name:** usgaap\_DisclosureTextBlockAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na  
**Period Type:** duration

X

- Definition

The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.

+ References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 275
- SubTopic 10
- Section 50
- Paragraph 2
- URI <http://asc.fasb.org/extlink&oid=51801978&loc=d3e6003-108592>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 275
- SubTopic 10
- Section 50
- Paragraph 2A
- URI <http://asc.fasb.org/extlink&oid=51801978&loc=SL51803626-108592>

+ Details

**Name:** us- gaap\_NatureOfOperations

**Namespace Prefix:** us- gaap\_

**Data Type:** nonnum:textBlockItemType

**Balance Type:** na

**Period Type:** duration

## 2. Basis of Presentation and Measurement

3 Months Ended  
Mar. 31, 2016

### Notes

#### 2. Basis of Presentation and Measurement

#### 2. BASIS OF PRESENTATION AND MEASUREMENT

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and the Securities Exchange Commission (“SEC”) instructions to Form 10-Q and Article 8 of SEC Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements and should be read in conjunction with Biotricity’s audited financial statements for the four months ended December 31, 2015 and year ended August 31, 2015 and notes thereto included in the Form 10-KT filed with the SEC on April 13, 2016 and iMedical’s audited financial statements for the years ended December 31, 2015 and 2014 and notes thereto included in the Form 8-K/A filed with the SEC on April 13, 2016. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of financial position and results of operations for the interim periods presented have been reflected herein. Operating results for the three months ended March 31, 2016, are not necessarily indicative of the results that may be expected for the year ending December 31, 2016.

#### X

##### - Definition

The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).

##### + References

No definition available.

##### + Details

**Name:** us- gaap\_BusinessDescriptionAndBasisOfPresentationTextBlock

**Namespace Prefix:** us- gaap\_

**Data Type:** nonnum:textBlockItemType

**Balance Type:** na

**Period Type:** duration

#### X

##### - References

No definition available.

##### + Details

**Name:** usgaap\_DisclosureTextBlockAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration



**3. Going  
Concern****3 Months Ended  
Mar. 31, 2016****Notes****3. Going  
Concern****3. GOING CONCERN**

The condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred recurring losses from operations and as at March 31, 2016 has an accumulated deficit of \$10,497,925. Management anticipates the Company will attain profitable status and improve its liquidity through continued business development and additional debt or equity investment in the Company. Management is pursuing various sources of financing.

On October 31, 2015, the Company engaged an agent to act as exclusive financial advisor to the Company with respect to assisting the Company in its capital raising efforts as well as assisting the Company in the review of potential financing alternatives available to it and to provide recommendations with respect to the options available to it for meeting its capital needs. Under the engagement agreement, the agent will represent the Company as the sole or lead placement agent, underwriter, book-runner or similar representation in its efforts to obtain financing of up to \$12 million in the form of a private placement, public offering, whether in one or a series of transactions, in a private or public offering of equity, convertible debt or equity, equity linked securities or any other securities.

The Company's continued existence is dependent upon its ability to continue to execute its operating plan and to obtain additional debt or equity financing. There can be no assurance that the necessary debt or equity financing will be available, or will be available on terms acceptable to the Company, in which case the Company may be unable to meet its obligations. Should the Company be unable to realize its assets and discharge its liabilities in the normal course of business, the net realizable value of its assets may be materially less than the amounts recorded in the condensed consolidated financial statements. The condensed consolidated financial statements do not include any adjustments relating to the recoverability of recorded asset amounts that might be necessary should the Company be unable to continue in existence.

**X****- References**

No definition available.

**+ Details****Name:** usgaap\_DisclosureTextBlockAbstract**Namespace Prefix:** us- gaap\_**Data Type:** xbrli:stringItemType**Balance Type:** na**Period Type:** duration

## X

### - Definition

The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.

### + References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 205
- SubTopic 40
- Section 50
- Paragraph 13
- URI <http://asc.fasb.org/extlink&oid=51888302&loc=SL51888449-203568>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 205
- SubTopic 40
- Section 50
- Paragraph 12
- URI <http://asc.fasb.org/extlink&oid=51888302&loc=SL51888443-203568>

### + Details

**Name:** us- gaap\_SubstantialDoubtAboutGoingConcernTextBlock

**Namespace Prefix:** us- gaap\_

**Data Type:** nonnum:textBlockItemType

**Balance Type:** na

**Period Type:** duration

**4. Summary of  
Significant  
Accounting  
Policies****3 Months Ended****Mar.. 31, 2016****Notes****4. Summary of  
Significant  
Accounting  
Policies****4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES***Use of Estimates*

The preparation of the condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas involving significant estimates and assumptions include: deferred income tax assets and related valuation allowance, accruals and valuation of warrants and stock options. Actual results could differ from those estimates. These estimates are reviewed periodically, and, as adjustments become necessary, they are reported in earnings in the period in which they become known.

*Earnings (Loss) Per Share*

The Company has adopted the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification ("ASC") Topic 260-10 which provides for calculation of "basic" and "diluted" earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. Diluted earnings per share exclude all potentially dilutive shares if their effect is anti-dilutive. There were no potentially dilutive shares outstanding as at March 31, 2016.

*Fair Value of Financial Instruments*

ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

Level 1 – Valuation based on quoted market prices in active markets for

identical assets or liabilities.

Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets.

Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management's best estimate of what market participants would use as fair value.

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash and accounts payable. The Company's cash, which is carried at fair value, is classified as a Level 1 financial instrument. The Company's bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk.

#### Recently Issued Accounting Pronouncements

In March 2016, the Company adopted the accounting pronouncement issued by the Financial Accounting Standards Board ("FASB") to update guidance on how companies account for certain aspects of share-based payments to employees. This pronouncement is effective for fiscal years beginning after December 15, 2016, and interim periods within those years, with early adoption permitted. This guidance requires all income tax effects of awards to be recognized in the income statement when the awards vest or are settled and changes the presentation of excess tax benefits on the statement of cash flows. The Company adopted these provisions on a prospective basis. In addition, this pronouncement changes guidance on: (a) accounting for forfeitures of share-based awards and (b) employers' accounting for an employee's use of shares to satisfy the employer's statutory income tax withholding obligation. The adoption of this pronouncement did not have a material impact on the Company's financial position and/or results of operations.

In February 2016, an accounting pronouncement was issued by the FASB to replace existing lease accounting guidance. This pronouncement is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet for most leases. Expenses associated with leases will continue to be recognized in a manner

similar to current accounting guidance. This pronouncement is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted. The adoption is required to be applied on a modified retrospective basis for each prior reporting period presented. The Company has not yet determined the effect that the adoption of this pronouncement may have on our financial position and/or results of operations.

On January 1, 2016, the Company adopted the accounting pronouncement issued by the FASB which eliminates the requirement that an acquirer in a business combination account for measurement-period adjustments retrospectively. Instead, an acquirer will recognize a measurement-period adjustment during the period in which it determines the amount of the adjustment. The adoption of this pronouncement did not have a material impact on the Company's financial position and/or results of operations.

On January 1, 2016, the Company adopted the accounting pronouncement issued by the FASB to update the guidance related to the presentation of debt issuance costs. This guidance requires debt issuance costs, related to a recognized debt liability, be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability rather than being presented as an asset. The Company adopted this pronouncement on a retrospective basis, and the adoption did not have a material impact on the Company financial position and/or results of operations.

In November 2015, an accounting pronouncement was issued by the FASB to simplify the presentation of deferred income taxes within the balance sheet. This pronouncement eliminates the requirement that deferred tax assets and liabilities are presented as current or noncurrent based on the nature of the underlying assets and liabilities. Instead, the pronouncement requires all deferred tax assets and liabilities, including valuation allowances, be classified as noncurrent. This pronouncement is effective for fiscal years beginning after December 15, 2016, with early adoption permitted. The Company intend to adopt this pronouncement on January 1, 2017, and the adoption will not have a material impact on our financial position and/or results of operations.

In May 2014, an accounting pronouncement was issued by the FASB to clarify existing guidance on revenue recognition. This guidance includes the required steps to achieve the core principle that a company should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This pronouncement is effective for fiscal years and interim periods beginning after December 15, 2017, with early adoption permitted. The guidance permits the use of one of two retrospective transition methods. We have not yet selected a transition method nor have the Company determined the effect that the adoption of the pronouncement may have on our financial position and/or results of operations.

## X

### - References

No definition available.

### + Details

**Name:** usgaap\_DisclosureTextBlockAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

## X

### - Definition

The entire disclosure for all significant accounting policies of the reporting entity.

### + References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 235
- SubTopic 10
- Section 50
- Paragraph 6
- URI <http://asc.fasb.org/extlink&oid=51655414&loc=d3e18861-107790>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 235
- SubTopic 10
- Section 50
- Paragraph 3
- URI <http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790>

Reference 3: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 235
- SubTopic 10
- Section 50
- Paragraph 1
- URI <http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790>

Reference 4: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 235
- SubTopic 10
- Section 50
- Paragraph 2
- URI <http://asc.fasb.org/extlink&oid=51655414&loc=d3e18743-107790>

Reference 5: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification

- Topic 235
- SubTopic 10
- Section 50
- Paragraph 5
- URI <http://asc.fasb.org/extlink&oid=51655414&loc=d3e18854-107790>

[+ Details](#)

**Name:** us- gaap\_SignificantAccountingPoliciesTextBlock

**Namespace Prefix:** us- gaap\_

**Data Type:** nonnum:textBlockItemType

**Balance Type:** na

**Period Type:** duration

**5. Due To  
Shareholders**

**3 Months Ended  
Mar. 31, 2016**

**Notes**

**5. Due To Shareholders 5. DUE TO SHAREHOLDERS**

Amounts due to related parties are unsecured, non-interest bearing and due on demand.

X

**- Definition**

Due to Shareholders Text Block.

**+ References**

No definition available.

**+ Details**

**Name:** fil\_DueToShareholdersTextBlock

**Namespace Prefix:** fil\_

**Data Type:** nonnum:textBlockItemType

**Balance Type:** na

**Period Type:** duration

X

**- References**

No definition available.

**+ Details**

**Name:** usgaap\_DisclosureTextBlockAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration



**6. Accounts  
Payable and  
Accrued  
Liabilities**

**3 Months Ended**

**Mar. 31, 2016**

[Notes](#)

[6. Accounts  
Payable and  
Accrued  
Liabilities](#)

**6. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES**

|                        | As at<br>March 31,<br>2016<br>\$ | As at December<br>31, 2015<br>\$ |
|------------------------|----------------------------------|----------------------------------|
| Trade accounts payable | 447,735                          | 274,055                          |
| Accrued liabilities    | 15,593                           | 139,218                          |
|                        | <u>463,328</u>                   | <u>413,273</u>                   |

**X**

**- Definition**

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

**+ References**

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 210

- SubTopic 10

- Section S99

- Paragraph 1

- Subparagraph (SX 210.5- 02.19(a),20,24)

- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682>

**+ Details**

**Name:** us- gaap\_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

**Namespace Prefix:** us- gaap\_

**Data Type:** nonnum:textBlockItemType

**Balance Type:** na

**Period Type:** duration

**X**

**- References**

No definition available.

**+ Details**

**Name:** usgaap\_DisclosureTextBlockAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

**7.  
Convertible  
Promissory  
Notes**

**3 Months Ended**

**Mar. 31, 2016**

Notes

7.

**7. CONVERTIBLE PROMISSORY NOTES**

Convertible  
Promissory  
Notes

Pursuant to a term sheet offering of \$2,000,000, the Company during the year ended December 31, 2015 issued convertible promissory notes to various accredited investors amounting to \$1,368,978. These notes have a maturity date of 24 months and carry annual interest rate of 11%. The note holders have the right until any time until the note is fully paid, to convert any outstanding and unpaid principal portion of the note, and accrued interest, into fully paid and non-assessable shares of Common Stock. The note has a conversion price initially set at \$1.78. Upon any future financings completed by the Company, the conversion price will reset to 75% of the future financing pricing. These notes do not contain prepayment penalties upon redemption. These debentures are secured by all of the present and after acquired property of the Company. However, the Company can force conversion of these notes, if during the term of the agreement, the Company completes a public listing and the Common Share price exceeds the conversion price for at least 20 consecutive trading days. At the closing of the Notes, the Company issued cash (7%) and warrants (7% of the number of Common Shares into which the Notes may be converted) to a brokers. The brokers receive 3% in cash and warrants for those investors in the Presidents List. The warrants have a term of 24 months and a similar reset provision based on future financings.

During March 2016, Biotricity commenced a bridge offering of up to an aggregate of \$1,000,000 of convertible promissory notes to various investors amounting to \$175,000. These notes have a maturity date of 12 months and carry an annual interest rate of 10%. The Bridge Notes principal is paid in cash and interest at 100% average 3 TD VWAP over the last 10 TD plus an embedded warrant at maturity. All of the outstanding principal and accrued interest shall convert (“Forced Conversion”) into units/securities upon the consummation of a Qualified Financing, based upon the lesser of: (i) \$1.65 per units/securities and (ii) the quotient obtained by dividing (x) the balance on the Forced Conversion date multiplied by 1.20 by (y) the actual price per unit/security in the Qualified Financing. Upon the Forced Conversion Date, the Holder shall further be issued Warrants exercisable into a number of shares of Common Stock equal to the number of Conversion Shares (but, in the case of units of securities, the primary equity security or the number of shares of Common Stock underlying the primary security if the primary security is not Common Stock).

The embedded conversion features and reset feature in the notes and broker warrants have been accounted for as a derivative liability based on FASB guidance (refer Note 8).

The movement in convertible promissory notes during the period ended March 31, 2016 is as follows:

|   | \$             |
|---|----------------|
| <b>Accreted value of convertible promissory notes as at December 31, 2015</b> | <b>783,778</b> |
| Face value of convertible promissory notes issued during March 2016           | 175,000        |
| Discount recognised at issuance due to embedded derivatives                   | (74,855)       |
| Accretion expense for Q1 2016   | 73,572         |
| <b>Accreted value of convertible promissory notes as at March 31, 2016</b>    | <b>957,495</b> |

These convertible notes have been presented on balance sheet as follows:

|             | \$             |
|-------------|----------------|
| Current     | 102,744        |
| Non-current | 854,751        |
|             | <b>957,495</b> |

As explained in detail in Note 9, all outstanding convertible promissory notes were exchanged/adjusted pursuant to Exchange Agreement effective February 2, 2016.

## X

### - Definition

The entire disclosure for information about short- term and long- term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own- share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long- term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

### + References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 505
- SubTopic 10
- Section 50
- Paragraph 3
- URI <http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475- 112644>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.5- 02.19,20,22)
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682>

[+ Details](#)

**Name:** us- gaap\_DebtDisclosureTextBlock

**Namespace Prefix:** us- gaap\_

**Data Type:** nonnum:textBlockItemType

**Balance Type:** na

**Period Type:** duration

**X**

[- References](#)

No definition available.

[+ Details](#)

**Name:** usgaap\_DisclosureTextBlockAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

**8.  
Derivative  
Liabilities**

**3 Months Ended**

**Mar. 31, 2016**

Notes

8. **8. DERIVATIVE LIABILITIES**

Derivative  
Liabilities

In connection with the sale of debt or equity instruments, the Company may sell options or warrants to purchase its common stock. In certain circumstances, these options or warrants are classified as derivative liabilities, rather than as equity. Additionally, the debt or equity instruments may contain embedded derivative instruments, such as embedded derivative features which in certain circumstances may be required to be bifurcated from the associated host instrument and accounted for separately as a derivative instrument liability.

The Company's derivative instrument liabilities are re-valued at the end of each reporting period, with changes in the fair value of the derivative liability recorded as charges or credits to income in the period in which the changes occur. For options, warrants and bifurcated embedded derivative features that are accounted for as derivative instrument liabilities, the Company estimates fair value using either quoted market prices of financial instruments with similar characteristics or other valuation techniques. The valuation techniques require assumptions related to the remaining term of the instruments and risk-free rates of return, our current common stock price and expected dividend yield, and the expected volatility of our common stock price over the life of the option.

The derivative liabilities arising from convertible promissory notes/warrants and related issuance of broker warrants are as follows:

|   | <b>Convertible<br/>notes/warrants</b> | <b>Broker<br/>warrants</b> | <b>Total</b>     |
|---|---------------------------------------|----------------------------|------------------|
|   | \$                                    | \$                         | \$               |
| <b>Derivative liabilities as at<br/>December 31, 2015</b> | <b>480,952</b>                        | <b>80,268</b>              | <b>561,220</b>   |
| Derivative fair value at issuance<br>during March 2016    | 74,855                                | -                          | 74,855           |
| Change in fair value of<br>derivatives                    | 591,044                               | 27,915                     | 618,959          |
| <b>Derivative liabilities as at<br/>March 31, 2016</b>    | <b>1,146,851</b>                      | <b>108,183</b>             | <b>1,255,034</b> |

These derivative liabilities have been presented on balance sheet as follows:

|             |           |
|-------------|-----------|
|             | \$        |
| Current     | 75,111    |
| Non-current | 1,179,923 |

---

---

**1,255,034**

---

The lattice methodology was used to value the derivative components, using the following assumptions at issuance and period end date of March 31, 2016:

**Assumptions**

|                            |               |
|----------------------------|---------------|
| Dividend yield             | 0.00%         |
| Risk-free rate for term    | 0.21% - 0.59% |
| Volatility                 | 100%-105%     |
| Remaining terms (years)    | 1.00 - 1.5    |
| Stock price (\$ per share) | 2.55 and 2.48 |

The projected annual volatility curve for valuation at issuance and period end was based on the comparable company's annual volatility. The Company used market trade stock prices at issuance and period end date.

X

[- Definition](#)

The entire disclosure for derivatives and fair value of assets and liabilities.

[+ References](#)

No definition available.

[+ Details](#)

**Name:** usgaap\_DerivativesAndFairValueTextBlock

**Namespace Prefix:** us- gaap\_

**Data Type:** nonnum:textBlockItemType

**Balance Type:** na

**Period Type:** duration

X

[- References](#)

No definition available.

[+ Details](#)

**Name:** usgaap\_DisclosureTextBlockAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

**9.  
Stockholders'  
Deficiency**

**3 Months Ended**

**Mar. 31, 2016**

**Notes**

**9.  
Stockholders'  
Deficiency**

**9. STOCKHOLDERS' DEFICIENCY**

**Authorized stock**

As at March 31, 2016, the Company is authorized to issue 125,000,000 shares of common stock (\$0.001 par value) and 10,000,000 shares of preferred stock (\$0.001 par value).

As explained below, in contemplation of the acquisition of iMedical on February 2, 2016, the Company's Board of Directors approved the increase in authorized capital stock from 100,000,000 shares of common stock to 125,000,000 shares of common stock, with a par value of \$0.001 per share, and from 1,000,000 shares of preferred stock to 10,000,000 shares of preferred stock, with a par value of \$0.001 per share.

**Issued and outstanding stock**

As explained in detail in Note 1 to the condensed consolidated financial statements, with the closing of the Acquisition Transaction on February 2, 2016:

- Biotricity's sole existing director resigned and a new director who is the sole director of the Company was appointed to fill the vacancy;
- Biotricity's sole Chief Executive Officer and sole officer, who beneficially owned 6,500,000 shares of outstanding common stock, resigned from all positions and transferred all of his shares back for cancellation;
- The existing management of the Company were appointed as executive officers; and
- The existing shareholders of the Company entered into a transaction whereby their existing common shares of the Company were exchanged for either (a) a new class of shares that are exchangeable for shares of Biotricity's common stock, or (b) shares of Biotricity's common stock, which (assuming exchange of all such exchangeable shares) would equal in the aggregate a number of shares of Biotricity's common stock that constitute 90% of Biotricity's issued and outstanding shares.

In addition, effective on the closing date of the acquisition transaction:

- Biotricity issued approximately 1.197 shares of its common stock in exchange for each common share of the Company held by the Company shareholders who in general terms, are not residents of Canada (for the purposes of the Income Tax Act (Canada)). Accordingly the Company issued 13,376,947 shares;

- Shareholders of the Company who in general terms, are Canadian residents (for the purposes of the Income Tax Act (Canada)) received approximately 1.197 Exchangeable Shares in the capital of Exchangeco in exchange for each common share of the Company held. Accordingly the Company issued 9,123,031 exchangeable shares;
- Each outstanding option to purchase common shares in the Company (whether vested or unvested) was exchanged, without any further action or consideration on the part of the holder of such option, for approximately 1.197 economically equivalent replacement options with an inverse adjustment to the exercise price of the replacement option to reflect the exchange ratio of approximately 1.197:1;
- Each outstanding warrant to purchase common shares in the Company was adjusted, in accordance with the terms thereof, such that it entitles the holder to receive approximately 1.197 shares of the common stock of Biotricity for each Warrant, with an inverse adjustment to the exercise price of the Warrants to reflect the exchange ratio of approximately 1.197:1
- Each outstanding advisor warrant to purchase common shares in the Company was adjusted, in accordance with the terms thereof, such that it entitles the holder to receive approximately 1.197 shares of the common stock of Biotricity for each Advisor Warrant, with an inverse adjustment to the exercise price of the Advisor Warrants to reflect the exchange ratio of approximately 1.197:1; and
- The outstanding 11% secured convertible promissory notes of the Company were adjusted, in accordance with the adjustment provisions thereof, as and from closing, so as to permit the holders to convert (and in some circumstances permit the Company to force the conversion of) the Convertible Debentures into shares of the common stock of Biotricity at a 25% discount to purchase price per share in Biotricity's next offering.

Issuance of preferred stock, common stock, exchangeable shares and cancellation of shares in connection with the reverse takeover transaction as explained above represents recapitalization of capital retroactively adjusting the accounting acquirer's legal capital to reflect the legal capital of the accounting acquiree as at August 31, 2015.

At March 31, 2016 and December 31, 2015 there were 15,876,947 and 9,000,000 shares of common stock issued and outstanding, respectively. There is currently one share of the Special Voting Preferred Stock issued and outstanding held by one holder of record, which is the Trustee in accordance with the terms of the Trust Agreement.

Out of outstanding common stock of 15,876,947 as at March 31, 2016, 750,000 are held in escrow and subject to forfeiture. Of the shares of Common Stock and exchangeable shares issued and outstanding approximately 22,500,000 of such shares are or would be restricted shares under the Securities Act.

#### **Stock-based compensation**



On March 30, 2015, iMedical approved Directors, Officers and Employees Stock Option Plan, under which it authorized and issued 3,000,000 options. This plan was established to enable the Company to attract and retain the services of highly qualified and experience directors, officers, employees and consultants and to give such person an interest in the success of the Company.

These options will expire by March 30, 2025. The outstanding options as at March 31, 2016 are as follows:

|                                | No. of options<br># | Exercise Price<br>\$ | Vested<br>options<br># | Unvested<br>options<br># |
|--------------------------------|---------------------|----------------------|------------------------|--------------------------|
| <b>As at December 31, 2015</b> | <b>167,500</b>      | <b>0.0001</b>        | -                      | <b>167,500</b>           |
| Adjustment*                    | 33,000              | -                    | -                      | 33,000                   |
| <b>As at March 31, 2016</b>    | <b>200,500</b>      | <b>0.0001</b>        | -                      | <b>200,500</b>           |

\* As explained above, on February 2, 2016 all outstanding options have been increased by a factor of 1.197.

#### **Broker warrants**

The outstanding broker warrants as at March 31, 2016 will expire by May 2018 as detailed below.

|                                | No. of broker<br>warrants<br># | Weighted<br>Average Exercise<br>Price<br>\$ |
|--------------------------------|--------------------------------|---|
| <b>As at December 31, 2015</b> | <b>271,742</b>                 | <b>1.2000</b>                               |
| Adjustment*                    | 53,503                         | (0.1970)                                    |
| <b>As at March 31, 2016</b>    | <b>325,245</b>                 | <b>1.0030</b>                               |

\* As explained above, on February 2, 2016 all outstanding broker warrants have been increased by a factor of 1.197.

#### **Warrants**

The outstanding warrants as at March 31, 2016 will expire by October 2016 as detailed below.

|                                | No. of warrants<br># | Weighted<br>Average Exercise<br>Price<br>\$ |
|--------------------------------|----------------------|---|
| <b>As at December 31, 2015</b> | <b>380,000</b>       | <b>1.0000</b>                               |
| Adjustment*                    | 74,860               | (0.1970)                                    |
| <b>As at March 31, 2016</b>    | <b>454,860</b>       | <b>0.8030</b>                               |

\* As explained above, on February 2, 2016 all outstanding warrants have been increased by a factor of 1.197.

X

- References

No definition available.

+ Details

**Name:** usgaap\_DisclosureTextBlockAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

X

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid- in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 235

- SubTopic 10

- Section S99

- Paragraph 1

- Subparagraph (SX 210.4- 08.(d),(e))

- URI <http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780- 122690>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 505

- SubTopic 10

- Section 50

- Paragraph 4

- URI <http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484- 112644>

Reference 3: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 310
- SubTopic 10
- Section S99
- Paragraph 2
- Subparagraph (SAB TOPIC 4.E)
- URI <http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707>

Reference 4: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 505
- SubTopic 10
- Section 50
- Paragraph 5
- URI <http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644>

Reference 5: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.5- 02.29- 31)
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682>

Reference 6: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 505
- SubTopic 10
- Section S99
- Paragraph 4
- Subparagraph (SAB TOPIC 4.C)
- URI <http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770>

Reference 7: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 505
- SubTopic 10
- Section 50
- Paragraph 6
- URI <http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644>

Reference 8: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 505
- SubTopic 10

- Section S99
- Paragraph 1
- Subparagraph (SX 210.3- 04)
- URI <http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770>

Reference 9: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 505
- SubTopic 30
- Section 50
- Paragraph 2
- URI <http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656>

Reference 10: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 505
- SubTopic 10
- Section 50
- Paragraph 3
- URI <http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644>

Reference 11: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Glossary Preferred Stock
- URI <http://asc.fasb.org/extlink&oid=6521494>

Reference 12: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 505
- SubTopic 10
- Section 50
- Paragraph 2
- URI <http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644>

Reference 13: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 505
- SubTopic 10
- Section 50
- Paragraph 11
- URI <http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644>

Reference 14: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC
- Name Staff Accounting Bulletin (SAB)
- Number Topic 4
- Section E

Reference 15: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC
- Name Staff Accounting Bulletin (SAB)
- Number Topic 4
- Section C

[+ Details](#)

**Name:** us- gaap\_StockholdersEquityNoteDisclosureTextBlock

**Namespace Prefix:** us- gaap\_

**Data Type:** nonnum:textBlockItemType

**Balance Type:** na

**Period Type:** duration

v3.4.0.3

**10. Related Party  
Transactions**

**3 Months Ended  
Mar. 31, 2016**

**Notes**

**10. Related Party  
Transactions**

**10. RELATED PARTY TRANSACTIONS**

The Company's transactions with related parties were carried out on normal commercial terms and in the course of the Company's business.

Other than those disclosed elsewhere in the financial statements, the related party transactions are as follows:

The Company paid consulting charges in cash to its stockholders amounting to \$43,680 and \$60,427 for the three months ended March 31, 2016 and 2015, respectively.

X

**- References**

No definition available.

**+ Details**

**Name:** usgaap\_DisclosureTextBlockAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**PeriodType:** duration

X

**- Definition**

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

**+ References**

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 850

- SubTopic 10

- Section 50

- Paragraph 3

- URI <http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 850

- SubTopic 10

- Section 50

- Paragraph 4

- URI <http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864>

Reference 3: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 850
- SubTopic 10
- Section 50
- Paragraph 1
- URI <http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864>

Reference 4: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 850
- SubTopic 10
- Section 50
- Paragraph 5
- URI <http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864>

Reference 5: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 850
- SubTopic 10
- Section 50
- Paragraph 6
- URI <http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864>

Reference 6: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 235
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.4- 08.(k))
- URI <http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690>

Reference 7: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC
- Name Regulation S- X (SX)
- Number 210
- Section 04
- Paragraph b
- Article 3A

[+ Details](#)

**Name:** usgaap\_RelatedPartyTransactionsDisclosureTextBlock

**Namespace Prefix:** us- gaap\_

**Data Type:** nonnum:textBlockItemType

**Balance Type:** na

**Period Type:** duration

**11.  
Commitments**

**3 Months Ended  
Mar. 31, 2016**

Notes

11.  
Commitments

**11. COMMITMENTS**

- a) On September 14, 2014, the Company finalized an agreement with CardioComm Solutions Inc. (“CardioComm”) for the development of a customized software for the ECG. The term of this agreement is later of 5 years or completion of all services from the effective date of agreement, which is September 14, 2014. Pursuant to this agreement, the Company paid CardioComm a non-refundable royalty advance of \$224,775 (CAD 250,000), which was fully expensed during year ended December 31, 2014 as the Company is still under research and development phase. In addition, the Company has committed to pay \$584,415 for design of a Windows Operating System ECG Management Software in accordance with an estimated payment schedules for the work performed. During the three months ended March 31, 2016 and 2015, Company paid \$65,520 and \$72,513, respectively which were expensed and included in research and development expenses.
- b) On July 4, 2014, the Company entered into an operating lease contract for its office premises in Mississauga, Ontario for a one year term. The monthly lease payment was \$3,910 which was increased to \$7,931. The lease agreement also include provisions of Cloud Hosting services at \$2,737 per month and telephone and internet services at \$1,173 per month.
- c) On January 8, 2016, the Company entered into a lease agreement for its office premises in California, USA for a monthly base rent of \$16,530.

**X**

**- Definition**

The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.

**+ References**

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 942

- SubTopic 210

- Section S99

- Paragraph 1

- Subparagraph (SX 210.9- 03.17)

- URI <http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878>



Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 944
- SubTopic 210
- Section S99
- Paragraph 1
- Subparagraph (SX 210.7- 03.(a)(19))
- URI <http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910>

Reference 3: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.5- 02.25)
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682>

[+ Details](#)

**Name:** us- gaap\_ CommitmentsDisclosureTextBlock

**Namespace Prefix:** us- gaap\_

**Data Type:** nonnum:textBlockItemType

**Balance Type:** na

**Period Type:** duration

**X**

- References

No definition available.

[+ Details](#)

**Name:** usgaap\_DisclosureTextBlockAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

**12.  
Subsequent  
Events**

**3 Months Ended  
Mar. 31, 2016**

[Notes](#)

[12.  
Subsequent  
Events](#)

**12. SUBSEQUENT EVENTS**

The Company's management has evaluated subsequent events up to May 16, 2016, the date the financial statements were issued, pursuant to the requirements of ASC 855 and has determined the following material subsequent events:

On May 3, 2016, the Company appointed Mr. David A. Rosa as director to fill the remaining vacancy on the Board of Directors of the Company. In connection with the appointment of Mr. Rosa, the Company authorized the issuance of warrants to purchase 40,000 shares of its common stock, at an exercise price per share of \$2.00, with such other terms and conditions as the officers of the Company deem reasonable and acceptable.

On April 27, 2016, the Company appointed Dr. Norman M. Betts as director to fill one of two vacancies on the Board of Directors. In connection with the appointment of Dr. Betts, the Company authorized the issuance of warrants to purchase 40,000 shares of its common stock, at an exercise price per share of \$2.00, with such other terms and conditions as the officers of the Company deem reasonable and acceptable.

During April, 2016, the Company entered into subscription agreements by and among the Company and the lending parties for the issuance of an aggregate principal amount of \$350,000 unsecured convertible promissory notes pursuant to offering to accredited investors for up to \$1,000,000 as explained in Note 7 to the condensed consolidated financial statements.

X

- References

No definition available.

+ Details

**Name:** usgaap\_DisclosureTextBlockAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

**Name:** us- gaap\_SubsequentEventsTextBlock  
**Namespace Prefix:** us- gaap\_  
**Data Type:** nonnum:textBlockItemType  
**Balance Type:** na  
**Period Type:** duration

v3.4.0.3

**4. Summary of  
Significant Accounting  
Policies: Use of  
Estimates (Policies)**

**3 Months Ended**

**Mar. 31, 2016**

**Policies**

**Use of Estimates**

**Use of Estimates**

The preparation of the condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas involving significant estimates and assumptions include: deferred income tax assets and related valuation allowance, accruals and valuation of warrants and stock options. Actual results could differ from those estimates. These estimates are reviewed periodically, and, as adjustments become necessary, they are reported in earnings in the period in which they become known.

X

**- References**

No definition available.

**+ Details**

**Name:** usgaap\_PolicyTextBlockAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

X

**- Definition**

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

**+ References**

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 275

- SubTopic 10

- Section 50

- Paragraph 4

- URI <http://asc.fasb.org/extlink&oid=51801978&loc=d3e6061-108592>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 275

- SubTopic 10

- Section 50

- Paragraph 9

- URI <http://asc.fasb.org/extlink&oid=51801978&loc=d3e6143-108592>

Reference 3: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 275

- SubTopic 10

- Section 50

- Paragraph 8

- URI <http://asc.fasb.org/extlink&oid=51801978&loc=d3e6132-108592>

[+ Details](#)

**Name:** us- gaap\_UseOfEstimates

**Namespace Prefix:** us- gaap\_

**Data Type:** nonnum:textBlockItemType

**Balance Type:** na

**Period Type:** duration

**4. Summary of  
Significant Accounting  
Policies: Earnings (loss)  
Per Share (Policies)**

**3 Months Ended**

**Mar. 31, 2016**

**Policies**

**Earnings (loss) Per Share**    *Earnings (Loss) Per Share*

The Company has adopted the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification ("ASC") Topic 260-10 which provides for calculation of "basic" and "diluted" earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. Diluted earnings per share exclude all potentially dilutive shares if their effect is anti-dilutive. There were no potentially dilutive shares outstanding as at March 31, 2016.

**X**

**- Definition**

Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balancesheet date of the latest reporting period but before the issuance of the financial statements.

**+ References**

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 260
- SubTopic 10
- Section 50
- Paragraph 1
- URI <http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 260
- SubTopic 10
- Section 50
- Paragraph 1
- Subparagraph (c)
- URI <http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257>

Reference 3: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 260

- SubTopic 10
- Section 50
- Paragraph 2
- URI <http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257>

Reference 4: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 235
- SubTopic 10
- Section 50
- Paragraph 3
- URI <http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790>

[+ Details](#)

**Name:** us- gaap\_EarningsPerSharePolicyTextBlock

**Namespace Prefix:** us- gaap\_

**Data Type:** nonnum:textBlockItemType

**Balance Type:** na

**Period Type:** duration

X

[- References](#)

No definition available.

[+ Details](#)

**Name:** usgaap\_PolicyTextBlockAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

**4. Summary of Significant  
Accounting Policies: Fair  
Value of Financial  
Instruments (Policies)**

**3 Months Ended**

**Mar. 31, 2016**

**Policies**

**Fair Value of Financial  
Instruments**

*Fair Value of Financial Instruments*

ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities.

Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets.

Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management's best estimate of what market participants would use as fair value.

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash and accounts payable. The Company's cash, which is carried at fair value, is classified as a Level 1 financial instrument. The Company's bank accounts are maintained with



financial institutions of reputable credit, therefore, bear minimal credit risk.

X

- [Definition](#)

Disclosure of accounting policy for determining the fair value of financial instruments.

+ [References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 235
- SubTopic 10
- Section 50
- Paragraph 3
- URI <http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 825
- SubTopic 10
- Section 50
- Paragraph 1
- URI <http://asc.fasb.org/extlink&oid=49121117&loc=d3e13279-108611>

Reference 3: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 820
- SubTopic 10
- Section 60
- Paragraph 1
- URI <http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260>

+ [Details](#)

**Name:** us- gaap\_FairValueOfFinancialInstrumentsPolicy

**Namespace Prefix:** us- gaap\_

**Data Type:** nonnum:textBlockItemType

**Balance Type:** na

**Period Type:** duration

X

- [References](#)

No definition available.

+ [Details](#)

**Name:** usgaap\_PolicyTextBlockAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

**4. Summary of Significant  
Accounting Policies: Recently  
Issued Accounting  
Pronouncements (Policies)**

**3 Months Ended**

**Mar. 31, 2016**

**Policies**

**Recently Issued Accounting  
Pronouncements**

**Recently Issued Accounting Pronouncements**

In March 2016, the Company adopted the accounting pronouncement issued by the Financial Accounting Standards Board ("FASB") to update guidance on how companies account for certain aspects of share-based payments to employees. This pronouncement is effective for fiscal years beginning after December 15, 2016, and interim periods within those years, with early adoption permitted. This guidance requires all income tax effects of awards to be recognized in the income statement when the awards vest or are settled and changes the presentation of excess tax benefits on the statement of cash flows. The Company adopted these provisions on a prospective basis. In addition, this pronouncement changes guidance on: (a) accounting for forfeitures of share-based awards and (b) employers' accounting for an employee's use of shares to satisfy the employer's statutory income tax withholding obligation. The adoption of this pronouncement did not have a material impact on the Company's financial position and/or results of operations.

In February 2016, an accounting pronouncement was issued by the FASB to replace existing lease accounting guidance. This pronouncement is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet for most leases. Expenses associated with leases will continue to be recognized in a manner similar to current accounting guidance. This pronouncement is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted. The adoption is required to be applied on a modified retrospective basis for each prior reporting period presented. The Company has not yet determined the effect that the adoption of this pronouncement may have on our financial position and/or results of operations.

On January 1, 2016, the Company adopted the accounting pronouncement issued by the FASB which eliminates the requirement that an acquirer in a business combination account for measurement-period adjustments retrospectively. Instead, an acquirer will recognize a measurement-period adjustment during the period in which it determines the amount of the adjustment. The adoption of this pronouncement did not have a material impact on the Company's financial position and/or results of operations.

On January 1, 2016, the Company adopted the accounting pronouncement issued by the FASB to update the guidance related to the presentation of debt issuance costs. This guidance requires debt issuance costs, related to a recognized debt liability, be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability rather than being presented as an asset. The Company adopted this pronouncement on a retrospective basis, and the adoption did not have a material impact on the Company financial position and/or results of operations.

In November 2015, an accounting pronouncement was issued by the FASB to simplify the presentation of deferred income taxes within the balance sheet. This pronouncement eliminates the requirement that deferred tax assets and liabilities are presented as current or noncurrent based on the nature of the underlying assets and liabilities. Instead, the pronouncement requires all deferred tax assets and liabilities, including valuation allowances, be classified as noncurrent. This pronouncement is effective for fiscal years beginning after December 15, 2016, with early adoption permitted. The Company intend to adopt this pronouncement on January 1, 2017, and the adoption will not have a material impact on our financial position and/or results of operations.

In May 2014, an accounting pronouncement was issued by the FASB to clarify existing guidance on revenue recognition. This guidance includes the required steps to achieve the core principle that a company should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This pronouncement is effective for fiscal years and interim periods beginning after December 15, 2017, with early adoption permitted. The guidance permits the use of one of two retrospective transition methods. We have not yet selected a transition method nor have the Company determined the effect that the adoption of the pronouncement may have on our financial position and/or results of operations.

[X](#)

[- Definition](#)

Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.

[+ References](#)

No definition available.

[+ Details](#)

**Name:** us- gaap\_NewAccountingPronouncementsPolicyPolicyTextBlock

**Namespace Prefix:** us- gaap\_

**Data Type:** nonnum:textBlockItemType

**Balance Type:** na

**Period Type:** duration

[X](#)

[- References](#)

No definition available.

[+ Details](#)

**Name:** usgaap\_PolicyTextBlockAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

**6. Accounts Payable  
and Accrued  
Liabilities: Schedule  
of Accounts Payable  
and Accrued  
Liabilities (Tables)**

**3 Months Ended**

**Mar. 31, 2016**

[Tables/Schedules](#)

[Schedule of Accounts  
Payable and Accrued  
Liabilities](#)

|                        | As at<br>March 31,<br>2016<br>\$ | As at December<br>31, 2015<br>\$ |
|------------------------|----------------------------------|----------------------------------|
| Trade accounts payable | 447,735                          | 274,055                          |
| Accrued liabilities    | 15,593                           | 139,218                          |
|                        | 463,328                          | 413,273                          |

X

- Definition

Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.

+ References

No definition available.

+ Details

**Name:** us- gaap\_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock

**Namespace Prefix:** us- gaap\_

**Data Type:** nonnum:textBlockItemType

**Balance Type:** na

**Period Type:** duration

X

- References

No definition available.

+ Details

**Name:** usgaap\_TableTextBlockSupplementAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

**7. Convertible  
Promissory Notes:  
Convertible Debt  
(Tables)**

**3 Months Ended**

**Mar. 31, 2016**

[Tables/Schedules](#)  
[Convertible Debt](#)

|   | \$             |
|---|----------------|
| <b>Accreted value of convertible promissory notes as at December 31, 2015</b> | <b>783,778</b> |
| Face value of convertible promissory notes issued during March 2016           | 175,000        |
| Discount recognised at issuance due to embedded derivatives                   | (74,855)       |
| Accretion expense for Q1 2016   | 73,572         |
| <b>Accreted value of convertible promissory notes as at March 31, 2016</b>    | <b>957,495</b> |

X

- Definition

Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.

+ References

No definition available.

+ Details

**Name:** usgaap\_ConvertibleDebtTableTextBlock

**Namespace Prefix:** us- gaap\_

**Data Type:** nonnum:textBlockItemType

**Balance Type:** na

**Period Type:** duration

X

- References

No definition available.

+ Details

**Name:** usgaap\_TableTextBlockSupplementAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

**7. Convertible  
Promissory Notes:  
Convertible Debt  
Table Text Block  
(Tables)**

**3 Months Ended**

**Mar. 31, 2016**

**Tables/Schedules**

**Convertible Debt Table  
Text Block**

|             |                |
|-------------|----------------|
|             | \$             |
| Current     | 102,744        |
| Non-current | 854,751        |
|             | <b>957,495</b> |

X

**- Definition**

Convertible Debt Table Text Block.

**+ References**

No definition available.

**+ Details**

**Name:** fil\_ConvertibleDebtTableTextBlock1TextBlock

**Namespace Prefix:** fil\_

**Data Type:** nonnum:textBlockItemType

**Balance Type:** na

**Period Type:** duration

X

**- References**

No definition available.

**+ Details**

**Name:** usgaap\_TableTextBlockSupplementAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

**8. Derivative Liabilities:  
Schedule of Derivative  
Assets at Fair Value  
(Tables)**

**3 Months Ended**

**Mar. 31, 2016**

[Tables/Schedules](#)

[Schedule of Derivative](#)

[Assets at Fair Value](#)

|   | Convertible<br>notes/warrants<br>\$ | Broker warrants<br>\$ | Total<br>\$      |
|---|-------------------------------------|-----------------------|------------------|
| <b>Derivative liabilities as at December 31, 2015</b> | <b>480,952</b>                      | <b>80,268</b>         | <b>561,220</b>   |
| Derivative fair value at issuance during March 2016   | 74,855                              | -                     | 74,855           |
| Change in fair value of derivatives                   | 591,044                             | 27,915                | 618,959          |
| <b>Derivative liabilities as at March 31, 2016</b>    | <b>1,146,851</b>                    | <b>108,183</b>        | <b>1,255,034</b> |

X

- Definition

Tabular disclosure of derivative assets at fair value.

+ References

No definition available.

+ Details

**Name:** usgaap\_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock

**Namespace Prefix:** us- gaap\_

**Data Type:** nonnum:textBlockItemType

**Balance Type:** na

**Period Type:** duration

X

- References

No definition available.

+ Details

**Name:** usgaap\_TableTextBlockSupplementAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration



**8. Derivative Liabilities:  
Schedule of Derivative  
Liabilities at Fair Value  
(Tables)**

**3 Months Ended**

**Mar. 31, 2016**

[Tables/Schedules](#)

[Schedule of Derivative  
Liabilities at Fair Value](#)

|             |                  |
|-------------|------------------|
|             | \$               |
| Current     | 75,111           |
| Non-current | 1,179,923        |
|             | <b>1,255,034</b> |

X

- Definition

Tabular disclosure of derivative liabilities at fair value.

+ References

No definition available.

+ Details

**Name:** usgaap\_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock

**Namespace Prefix:** us- gaap\_

**Data Type:** nonnum:textBlockItemType

**Balance Type:** na

**Period Type:** duration

X

- References

No definition available.

+ Details

**Name:** usgaap\_TableTextBlockSupplementAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

**8. Derivative  
Liabilities: Schedule of  
Share-based Payment  
Award, Stock Options,  
Valuation  
Assumptions (Tables)**

**3 Months Ended**

**Mar. 31, 2016**

**Tables/Schedules**

**Schedule of Share-based  
Payment Award, Stock  
Options, Valuation  
Assumptions**

**Assumptions**

|                            |               |
|----------------------------|---------------|
| Dividend yield             | 0.00%         |
| Risk-free rate for term    | 0.21% - 0.59% |
| Volatility                 | 100%-105%     |
| Remaining terms (years)    | 1.00 - 1.5    |
| Stock price (\$ per share) | 2.55 and 2.48 |

X

- Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk- free rate(s), and (e) discount for post- vesting restrictions.

+ References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 718
- SubTopic 10
- Section 50
- Paragraph 2
- Subparagraph (f)(2)
- URI <http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901>

+ Details

**Name:** us- gaap\_ ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

**Namespace Prefix:** us- gaap\_

**Data Type:** nonnum:textBlockItemType

**Balance Type:** na

**Period Type:** duration

X

- References

No definition available.

+ Details

**Name:** usgaap\_TableTextBlockSupplementAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

v3.4.0.3

**9. Stockholders'  
Deficiency: Schedule of  
Share-based  
Compensation, Activity  
(Tables)**

**3 Months Ended**

**Mar. 31, 2016**

[Tables/Schedules](#)

[Schedule of Share-based  
Compensation, Activity](#)

|                                    | No. of<br>options<br># | Exercise<br>Price<br>\$ | Vested<br>options<br># | Unvested<br>options<br># |
|------------------------------------|------------------------|-------------------------|------------------------|--------------------------|
| <b>As at December 31,<br/>2015</b> | <b>167,500</b>         | <b>0.0001</b>           | -                      | <b>167,500</b>           |
| Adjustment*                        | 33,000                 | -                       | -                      | 33,000                   |
| <b>As at March 31, 2016</b>        | <b>200,500</b>         | <b>0.0001</b>           | -                      | <b>200,500</b>           |

X

- Definition

Tabular disclosure of share- based compensation plans that may be presented in a single table for outstanding, vested and expected to vest, and exercisable awards. The information that may be disclosed in this table may include, but is not limited to, number of shares, weighted average exercise price, weighted average remaining contractual life, and aggregate intrinsic value.

+ References

No definition available.

+ Details

**Name:** us- gaap\_ScheduleOfShareBasedCompensationActivityTableTextBlock

**Namespace Prefix:** us- gaap\_

**Data Type:** nonnum:textBlockItemType

**Balance Type:** na

**Period Type:** duration

X

- References

No definition available.

+ Details

**Name:** usgaap\_TableTextBlockSupplementAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

**9. Stockholders'  
Deficiency: Schedule  
of Stockholders'  
Equity Note, Warrants  
or Rights (Tables)**

**3 Months Ended**

**Mar. 31, 2016**

**Tables/Schedules**

**Schedule of  
Stockholders' Equity  
Note, Warrants or  
Rights**

|                                | <b>No. of broker<br/>warrants<br/>#</b> | <b>Weighted<br/>Average Exercise<br/>Price<br/>\$</b> |
|--------------------------------|---|---|
| <b>As at December 31, 2015</b> | <b>271,742</b>                          | <b>1.2000</b>   |
| Adjustment*                    | 53,503                                  | (0.1970)  |
| <b>As at March 31, 2016</b>    | <b>325,245</b>                          | <b>1.0030</b>   |

\* As explained above, on February 2, 2016 all outstanding broker warrants have been increased by a factor of 1.197.

**Warrants**

The outstanding warrants as at March 31, 2016 will expire by October 2016 as detailed below.

|                                | <b>No. of warrants<br/>#</b> | <b>Weighted<br/>Average Exercise<br/>Price<br/>\$</b> |
|--------------------------------|------------------------------|---|
| <b>As at December 31, 2015</b> | <b>380,000</b>               | <b>1.0000</b>   |
| Adjustment*                    | 74,860                       | (0.1970)  |
| <b>As at March 31, 2016</b>    | <b>454,860</b>               | <b>0.8030</b>   |

**X**

**- Definition**

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants

and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

#### + References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 235
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.4- 08.(i))
- URI <http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 718
- SubTopic 10
- Section 50
- Paragraph 1
- Subparagraph (a)
- URI <http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901>

Reference 3: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 505
- SubTopic 50
- Section S99
- Paragraph 1
- URI <http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775>

Reference 4: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 505
- SubTopic 50
- Section 50
- Paragraph 1
- URI <http://asc.fasb.org/extlink&oid=51659978&loc=d3e25284-112666>

Reference 5: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC
- Name Regulation S- X (SX)
- Number 210
- Section 02
- Paragraph 28
- Article 5

#### + Details

**Name:** us- gaap\_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock

**Namespace Prefix:** us- gaap\_

**Data Type:** nonnum:textBlockItemType

**Balance Type:** na

**Period Type:** duration

[X](#)

[- References](#)

No definition available.

[+ Details](#)

**Name:** usgaap\_TableTextBlockSupplementAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

v3.4.0.3

**3. Going Concern (Details) - USD (\$)**                      **Mar. 31, 2016**                      **Dec. 31, 2015**

**Details**

**Accumulated deficit**    \$ 10,497,925                      \$ 9,228,774

X

- **Definition**

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ **References**

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.5- 02.31(a)(3))
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212- 122682>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC
- Name Regulation S- X (SX)
- Number 210
- Section 04
- Article 3

+ **Details**

**Name:** us- gaap\_RetainedEarningsAccumulatedDeficit

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

X

- **References**

No definition available.

+ **Details**

**Name:** usgaap\_TextBlockAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

v3.4.0.3

| <b>6. Accounts Payable and Accrued Liabilities: Schedule of Accounts Payable and Accrued Liabilities (Details) - USD (\$)</b> | <b>Mar. 31,<br/>2016</b> | <b>Dec. 31,<br/>2015</b> |
|---|--------------------------|--------------------------|
|---|--------------------------|--------------------------|

[Details](#)

|   |            |            |
|---|------------|------------|
| <u><a href="#">Accounts Payable, Trade, Current</a></u> | \$ 447,735 | \$ 274,055 |
| <u><a href="#">Accrued compensation and other</a></u>   | \$ 15,593  | \$ 139,218 |

X

[- Definition](#)

Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Glossary Current Liabilities
- URI <http://asc.fasb.org/extlink&oid=6509677>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section 45
- Paragraph 8
- URI <http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765>

Reference 3: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.5- 02.19(a))
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682>

[+ Details](#)

**Name:** usgaap\_AccountsPayableTradeCurrent

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

X

[- Definition](#)

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>



- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.5- 02.20)
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682>

[+ Details](#)

**Name:** us- gaap\_AccruedLiabilitiesCurrent

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

**X**

[- References](#)

No definition available.

[+ Details](#)

**Name:** usgaap\_TextBlockAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

v3.4.0.3

**7. Convertible Promissory Notes: Convertible Debt  
(Details) - USD (\$)**

**3 Months Ended**  
**Mar. 31, Mar. 31, Dec. 31,**  
**2016 2015 2015**

**Details**

|   |            |  |            |
|---|------------|--|------------|
| <a href="#">Accreted value of Convertible Promissory Notes</a>  |            |  | \$ 783,778 |
| <a href="#">Face Value Convertible Promissory Note Issued</a>   | \$ 175,000 |  |            |
| <a href="#">Discount Recognized due to Embedded Derivatives</a> | (74,855)   |  |            |
| <a href="#">Accretion expense</a>                               | [1] 73,572 |  |            |
| <a href="#">Accreted Value of Convertible Notes</a>             | \$ 957,495 |  |            |

[1] See Note 7

X

**- Definition**

Accreted Value of Convertible Notes.

**+ References**

No definition available.

**+ Details**

**Name:** fil\_AccretedValueOfConvertibleNotes

**Namespace Prefix:** fil\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

X

**- Definition**

Accreted value of Convertible Promissory Notes.

**+ References**

No definition available.

**+ Details**

**Name:** fil\_AccretedValueOfConvertiblePromissoryNotes

**Namespace Prefix:** fil\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

X

**- Definition**

Discount Recognized due to Embedded Derivatives.

**+ References**

No definition available.

**+ Details**

**Name:** fil\_DiscountRecognizedDueToEmbeddedDerivatives

**Namespace Prefix:** fil\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

X

- Definition

Face Value Convertible Promissory Note Issued.

+ References

No definition available.

+ Details

**Name:** fil\_FaceValueConvertiblePromissoryNoteIssued

**Namespace Prefix:** fil\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

X

- Definition

Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.

+ References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 410

- SubTopic 20

- Section 45

- Paragraph 1

- URI <http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 420

- SubTopic 10

- Section 35

- Paragraph 4

- URI <http://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866>

+ Details

**Name:** us- gaap\_AccretionExpense

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** debit

**Period Type:** duration

X

- References

No definition available.

+ Details

**Name:** usgaap\_TextBlockAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

v3.4.0.3

**7. Convertible Promissory Notes: Convertible Debt Table Text Block (Details)** **Mar. 31, 2016**  
**USD (\$)**

**Details**

|  |            |
|--|------------|
| <a href="#">Convertible Debt, Current</a>    | \$ 102,744 |
| <a href="#">Convertible Debt, Noncurrent</a> | \$ 854,751 |

X

**- Definition**

The portion of the carrying value of long- term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.

**+ References**

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.5- 02.20)
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212- 122682>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC
- Name Regulation S- X (SX)
- Number 210
- Section 02
- Paragraph 19, 20
- Article 5

**+ Details**

**Name:** us- gaap\_ConvertibleDebtCurrent

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

X

**- Definition**

Carrying amount of long- term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.

**+ References**

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.5- 02.22)

- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682>

[+ Details](#)

**Name:** us- gaap\_ConvertibleDebtNoncurrent

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

[X](#)

[- References](#)

No definition available.

[+ Details](#)

**Name:** usgaap\_TextBlockAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

v3.4.0.3

| <b>8. Derivative Liabilities: Schedule of Derivative Assets at Fair Value<br/>(Details) - USD (\$)</b> | <b>Mar. 31,<br/>2016</b> | <b>Dec. 31,<br/>2015</b> |
|--|--------------------------|--------------------------|
| <a href="#">Derivative liabilities</a> [1]   | \$ 75,111                |                          |
| <a href="#">Convertible Notes/warrants</a>   |                          |                          |
| <a href="#">Derivative liabilities</a>   | 1,146,851                | \$ 480,952               |
| <a href="#">Derivative Liability, Fair Value, Gross Liability</a>                                      | 74,855                   |                          |
| <a href="#">Change in Fair Value of Derivatives</a>  | 591,044                  |                          |
| <a href="#">Broker Warrants</a>  |                          |                          |
| <a href="#">Derivative liabilities</a>   | 108,183                  | 80,268                   |
| <a href="#">Change in Fair Value of Derivatives</a>  | 27,915                   |                          |
| <a href="#">Total</a>  |                          |                          |
| <a href="#">Derivative liabilities</a>   | 1,255,034                | \$ 561,220               |
| <a href="#">Derivative Liability, Fair Value, Gross Liability</a>                                      | 74,855                   |                          |
| <a href="#">Change in Fair Value of Derivatives</a>  | \$ 618,959               |                          |

[1] See Note 8

X

- Definition

Change in Fair Value of Derivatives.

+ References

No definition available.

+ Details

**Name:** fil\_ChangeInFairValueOfDerivatives

**Namespace Prefix:** fil\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** debit

**Period Type:** instant

X

- Definition

Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.

+ References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 860

- SubTopic 20

- Section 50

- Paragraph 4D

- Subparagraph (c)(2)

- URI <http://asc.fasb.org/extlink&oid=51814546&loc=SL51823488-111719>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification
- Topic 210
- SubTopic 20
- Section 50
- Paragraph 3
- Subparagraph (a)
- URI <http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312>

Reference 3: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 815
- SubTopic 10
- Section 50
- Paragraph 4B
- Subparagraph (a),(c)
- URI <http://asc.fasb.org/extlink&oid=56946850&loc=SL5624163-113959>

Reference 4: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 20
- Section 55
- Paragraph 7
- URI <http://asc.fasb.org/extlink&oid=51825145&loc=SL20226000-175313>

[+ Details](#)

**Name:** usgaap\_DerivativeFairValueOfDerivativeLiability

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

**X**

[- Definition](#)

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 20
- Section 50
- Paragraph 3
- Subparagraph (c)
- URI <http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification

- Glossary Current Liabilities
- URI <http://asc.fasb.org/extlink&oid=6509677>

Reference 3: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 815
- SubTopic 10
- Section 45
- Paragraph 5
- URI <http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958>

Reference 4: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 815
- SubTopic 10
- Section 45
- Paragraph 6
- URI <http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958>

Reference 5: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 825
- SubTopic 10
- Section 50
- Paragraph 10
- Subparagraph (a)
- URI <http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611>

Reference 6: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 825
- SubTopic 10
- Section 50
- Paragraph 15
- URI <http://asc.fasb.org/extlink&oid=49121117&loc=d3e13495-108611>

[+ Details](#)

**Name:** us- gaap\_DerivativeLiabilitiesCurrent

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

[X](#)

[- Details](#)

**Name:** fil\_DerivativeLiabilities1Axis=fil\_ConvertibleNotesWarrantsMember

**Namespace Prefix:**

**Data Type:** na

**Balance Type:**

**Period Type:**



X

[- Details](#)

**Name:** fil\_DerivativeLiabilities1Axis=fil\_BrokerWarrantsMember

**Namespace Prefix:**

**Data Type:** na

**Balance Type:**

**Period Type:**

X

[- Details](#)

**Name:** fil\_DerivativeLiabilities1Axis=fil\_TotalMember

**Namespace Prefix:**

**Data Type:** na

**Balance Type:**

**Period Type:**

v3.4.0.3

| <b>8. Derivative Liabilities: Schedule of Derivative Liabilities at Fair Value<br/>(Details) - USD (\$)</b> | <b>Mar. 31,<br/>2016</b> | <b>Dec. 31,<br/>2015</b> |
|---|--------------------------|--------------------------|
|---|--------------------------|--------------------------|

**Details**

|  |     |              |
|--|-----|--------------|
| <a href="#">Derivative liabilities</a>           | [1] | \$ 75,111    |
| <a href="#">Derivative Liability, Noncurrent</a> |     | \$ 1,179,923 |

[1] See Note 8

**X**

**- Definition**

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.

**+ References**

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 20
- Section 50
- Paragraph 3
- Subparagraph (c)
- URI <http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Glossary Current Liabilities
- URI <http://asc.fasb.org/extlink&oid=6509677>

Reference 3: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 815
- SubTopic 10
- Section 45
- Paragraph 5
- URI <http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958>

Reference 4: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 815
- SubTopic 10
- Section 45
- Paragraph 6
- URI <http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958>

Reference 5: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification
- Topic 825
- SubTopic 10
- Section 50
- Paragraph 10
- Subparagraph (a)
- URI <http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611>

Reference 6: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 825
- SubTopic 10
- Section 50
- Paragraph 15
- URI <http://asc.fasb.org/extlink&oid=49121117&loc=d3e13495-108611>

[+ Details](#)

**Name:** us- gaap\_DerivativeLiabilitiesCurrent

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

**X**

[- Definition](#)

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 20
- Section 50
- Paragraph 3
- Subparagraph (c)
- URI <http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 815
- SubTopic 10
- Section 45
- Paragraph 5
- URI <http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958>

Reference 3: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 825

- SubTopic 10
- Section 50
- Paragraph 10
- Subparagraph (a)
- URI <http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611>

Reference 4: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 815
- SubTopic 10
- Section 45
- Paragraph 6
- URI <http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958>

Reference 5: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 825
- SubTopic 10
- Section 50
- Paragraph 15
- URI <http://asc.fasb.org/extlink&oid=49121117&loc=d3e13495-108611>

[+ Details](#)

**Name:** us- gaap\_DerivativeLiabilitiesNoncurrent

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

X

[- References](#)

No definition available.

[+ Details](#)

**Name:** usgaap\_TextBlockAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

**3 Months  
Ended  
Mar. 31,  
2016**

**8. Derivative Liabilities: Schedule of Share-based Payment Award, Stock Options,  
Valuation Assumptions (Details) - Assumptions**

|  |         |
|--|---------|
| <a href="#">Fair Value Assumptions, Expected Volatility Rate</a>   | 0.00%   |
| <a href="#">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</a>  | 0.21%   |
| <a href="#">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</a>  | 0.59%   |
| <a href="#">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</a> | 100.00% |
| <a href="#">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</a> | 105.00% |
| <a href="#">Remaining Term 1</a>   | 1.00    |
| <a href="#">Remaining Term 2</a>   | 1.5     |
| <a href="#">Stock Price</a>  | 2.55    |
| <a href="#">Stock Price2</a>   | 2.48    |

X

- Definition

Remaining Term, in years.

+ References

No definition available.

+ Details

**Name:** fil\_RemainingTerm1

**Namespace Prefix:** fil\_

**Data Type:** xbrli:decimalItemType

**Balance Type:** na

**Period Type:** duration

X

- Definition

Remaining Term, in years.

+ References

No definition available.

+ Details

**Name:** fil\_RemainingTerm2

**Namespace Prefix:** fil\_

**Data Type:** xbrli:decimalItemType

**Balance Type:** na

**Period Type:** duration

X

- Definition

Stock Price.

+ References

No definition available.

+ Details

**Name:** fil\_StockPrice  
**Namespace Prefix:** fil\_  
**Data Type:** xbrli:decimalItemType  
**Balance Type:** na  
**Period Type:** duration

X

- [Definition](#)

Stock Price.

+ [References](#)

No definition available.

+ [Details](#)

**Name:** fil\_StockPrice2  
**Namespace Prefix:** fil\_  
**Data Type:** xbrli:decimalItemType  
**Balance Type:** na  
**Period Type:** duration

X

- [Definition](#)

Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.

+ [References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 820

- SubTopic 10

- Section 50

- Paragraph 2

- Subparagraph (e)

- URI <http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258>

+ [Details](#)

**Name:** us- gaap\_FairValueAssumptionsExpectedVolatilityRate  
**Namespace Prefix:** us- gaap\_  
**Data Type:** num:percentItemType  
**Balance Type:** na  
**Period Type:** duration

X

- [Definition](#)

The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability- weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+ [References](#)

No definition available.

+ [Details](#)

**Name:** usgaap\_  
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum  
**Namespace Prefix:** us- gaap\_

**Data Type:** num:percentItemType

**Balance Type:** na

**Period Type:** duration

X

[- Definition](#)

The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability- weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

[+ References](#)

No definition available.

[+ Details](#)

**Name:** usgaap\_

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum

**Namespace Prefix:** us- gaap\_

**Data Type:** num:percentItemType

**Balance Type:** na

**Period Type:** duration

X

[- Definition](#)

The maximum risk- free interest rate assumption that is used in valuing an option on its own shares.

[+ References](#)

No definition available.

[+ Details](#)

**Name:** usgaap\_

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum

**Namespace Prefix:** us- gaap\_

**Data Type:** num:percentItemType

**Balance Type:** na

**Period Type:** duration

X

[- Definition](#)

The minimum risk- free interest rate assumption that is used in valuing an option on its own shares.

[+ References](#)

No definition available.

[+ Details](#)

**Name:** usgaap\_

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum

**Namespace Prefix:** us- gaap\_

**Data Type:** num:percentItemType

**Balance Type:** na

**Period Type:** duration

X

- Details

**Name:** fil\_AssumptionsAxis=fil\_AssumptionsMember

**Namespace Prefix:**

**Data Type:** na

**Balance Type:**

**Period Type:**



v3.4.0.3

**9. Stockholders' Deficiency (Details) - \$ / shares**      **Mar. 31, 2016**      **Dec. 31, 2015**

[Details](#)

|   |             |             |
|---|-------------|-------------|
| <u><a href="#">Common Stock, Shares Authorized</a></u>    | 125,000,000 | 100,000,000 |
| <u><a href="#">Common Stock, Par Value</a></u>            | \$ 0.001    | \$ 0.001    |
| <u><a href="#">Preferred Stock, Shares Authorized</a></u> | 10,000,000  | 1,000,000   |
| <u><a href="#">Preferred Stock, Par Value</a></u>         | \$ 0.001    | \$ 0.001    |

X

- [Definition](#)

Face amount or stated value per share of common stock.

+ [References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.5- 02.29)
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212- 122682>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC
- Name Regulation S- X (SX)
- Number 210
- Section 02
- Paragraph 30
- Article 5

+ [Details](#)

**Name:** usgaap\_CommonStockParOrStatedValuePerShare

**Namespace Prefix:** us- gaap\_

**Data Type:** num:perShareItemType

**Balance Type:** na

**Period Type:** instant

X

- [Definition](#)

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ [References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.5- 02.29)
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212- 122682>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC
- Name Regulation S- X (SX)
- Number 210
- Section 02
- Paragraph 30
- Article 5

[+ Details](#)

**Name:** us- gaap\_CommonStockSharesAuthorized

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:sharesItemType

**Balance Type:** na

**Period Type:** instant

X

[- Definition](#)

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10
- Section S99
- Paragraph 1
- Subparagraph (SX 210.5- 02.28)
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212- 122682>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC
- Name Regulation S- X (SX)
- Number 210
- Section 02
- Paragraph 29
- Article 5

[+ Details](#)

**Name:** us- gaap\_PREFERREDStockParOrStatedValuePerShare

**Namespace Prefix:** us- gaap\_

**Data Type:** num:perShareItemType

**Balance Type:** na

**Period Type:** instant

X

[- Definition](#)

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 210
- SubTopic 10

- Section S99
- Paragraph 1
- Subparagraph (SX 210.5- 02.28)
- URI <http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC
- Name Regulation S- X (SX)
- Number 210
- Section 02
- Paragraph 29
- Article 5

[+ Details](#)

**Name:** us- gaap\_PreferredStockSharesAuthorized

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:sharesItemType

**Balance Type:** na

**Period Type:** instant

[X](#)

[- References](#)

No definition available.

[+ Details](#)

**Name:** usgaap\_TextBlockAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

| 9. Stockholders' Deficiency: Schedule of Share-based Compensation,<br>Activity (Details) - \$ / shares                              | 3 Months<br>Ended |                  |
|---|-------------------|------------------|
|   | Mar. 31,<br>2016  | Dec. 31,<br>2015 |
| <u>Details</u>  |                   |                  |
| <u>Share-based Compensation Arrangement by Share-based Payment Award,<br/>Options, Outstanding, Number</u>                          | 200,500           | 167,500          |
| <u>Share-based Compensation Arrangement by Share-based Payment Award,<br/>Options, Outstanding, Weighted Average Exercise Price</u> | \$ 0.0001         | \$ 0.0001        |
| <u>Share Based Compensation Arrangement by Share Based Payment Award<br/>Unvested Options</u>                                       | 200,500           | 167,500          |
| <u>Options Adjusted</u>   | 33,000            |                  |
| <u>Share Based Compensation Arrangement by Share Based Payment Award<br/>Unvested Options Adjusted</u>                              | 33,000            |                  |

X

- Definition

Options Adjusted.

+ References

No definition available.

+ Details

**Name:** fil\_OptionsAdjusted**Namespace Prefix:** fil\_**Data Type:** xbrli:sharesItemType**Balance Type:** na**Period Type:** duration

X

- Definition

Share Based Compensation Arrangement by Share Based Payment Award Unvested Options.

+ References

No definition available.

+ Details

**Name:** fil\_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnvestedOptions**Namespace Prefix:** fil\_**Data Type:** xbrli:sharesItemType**Balance Type:** na**Period Type:** instant

X

- Definition

Share Based Compensation Arrangement by Share Based Payment Award Unvested Options Adjusted.

+ References

No definition available.

+ Details

**Name:** fil\_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnvestedOptionsAdjusted**Namespace Prefix:** fil\_**Data Type:** xbrli:sharesItemType**Balance Type:** na

**Period Type:** instant

X

- [Definition](#)

Number of options outstanding, including both vested and non- vested options.

+ [References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 718
- SubTopic 10
- Section 50
- Paragraph 2
- URI <http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 718
- SubTopic 10
- Section 50
- Paragraph 2
- Subparagraph (c)(1)(i)- (ii)
- URI <http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901>

+ [Details](#)

**Name:** usgaap\_

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:sharesItemType

**Balance Type:** na

**Period Type:** instant

X

- [Definition](#)

Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.

+ [References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 718
- SubTopic 10
- Section 50
- Paragraph 2
- Subparagraph (c)(1)(i)
- URI <http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901>

+ [Details](#)

**Name:** usgaap\_

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

**Namespace Prefix:** us- gaap\_

**Data Type:** num:perShareItemType

**Balance Type:** na

**Period Type:** instant

[X](#)

[- References](#)

No definition available.

[+ Details](#)

**Name:** usgaap\_TextBlockAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

| 9. Stockholders' Deficiency: Schedule of Stockholders' Equity Note,<br>Warrants or Rights (Details) - \$ / shares | 3 Months<br>Ended |                  |
|---|-------------------|------------------|
|   | Mar. 31,<br>2016  | Dec. 31,<br>2015 |
| <u>Details</u>  |                   |                  |
| <u>Broker Warrants Outstanding</u>  | 325,245           | 271,742          |
| <u>Broker Warrants Outstanding Exercise Price</u>   | \$ 1.0030         | \$ 1.2000        |
| <u>Broker Warrants Outstanding Adjusted</u>   | 53,503            |                  |
| <u>Broker Warrants Outstanding Adjusted Exercise Price</u>  | \$ (0.1970)       |                  |
| <u>Class of Warrant or Right, Outstanding</u>   | 454,860           | 380,000          |
| <u>Class of Warrant or Right, Exercise Price of Warrants or Rights</u>  | \$ 0.8030         | \$ 1.0000        |
| <u>Warrants Adjusted</u>  | 74,860            |                  |
| <u>Warrants Adjusted Exercise Price</u>   | \$ (0.1970)       |                  |

X

- Definition

Broker Warrants Outstanding.

+ References

No definition available.

+ Details

**Name:** fil\_BrokerWarrantsOutstanding**Namespace Prefix:** fil\_**Data Type:** xbrli:sharesItemType**Balance Type:** na**Period Type:** instant

X

- Definition

Broker Warrants Outstanding Adjusted.

+ References

No definition available.

+ Details

**Name:** fil\_BrokerWarrantsOutstandingAdjusted**Namespace Prefix:** fil\_**Data Type:** xbrli:sharesItemType**Balance Type:** na**Period Type:** duration

X

- Definition

Broker Warrants Outstanding Adjusted Exercise Price.

+ References

No definition available.

+ Details

**Name:** fil\_BrokerWarrantsOutstandingAdjustedExercisePrice**Namespace Prefix:** fil\_**Data Type:** num:perShareItemType**Balance Type:** na

**Period Type:** duration

X

- [Definition](#)

Broker Warrants Outstanding Exercise Price.

+ [References](#)

No definition available.

+ [Details](#)

**Name:** fil\_BrokerWarrantsOutstandingExercisePrice

**Namespace Prefix:** fil\_

**Data Type:** num:perShareItemType

**Balance Type:** na

**Period Type:** instant

X

- [Definition](#)

Warrants Adjusted.

+ [References](#)

No definition available.

+ [Details](#)

**Name:** fil\_WarrantsAdjusted

**Namespace Prefix:** fil\_

**Data Type:** xbrli:sharesItemType

**Balance Type:** na

**Period Type:** duration

X

- [Definition](#)

Warrants Adjusted Exercise Price.

+ [References](#)

No definition available.

+ [Details](#)

**Name:** fil\_WarrantsAdjustedExercisePrice

**Namespace Prefix:** fil\_

**Data Type:** num:perShareItemType

**Balance Type:** na

**Period Type:** duration

X

- [Definition](#)

Exercise price per share or per unit of warrants or rights outstanding.

+ [References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 235

- SubTopic 10

- Section S99

- Paragraph 1

- Subparagraph (SX 210.4- 08.(i)(4))

- URI <http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690>

+ [Details](#)

**Name:** usgaap\_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1



**Namespace Prefix:** us- gaap\_  
**Data Type:** num:perShareItemType  
**Balance Type:** na  
**Period Type:** instant

X

- [Definition](#)

Number of warrants or rights outstanding.

+ [References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 235

- SubTopic 10

- Section S99

- Paragraph 1

- Subparagraph (SX 210.4- 08.(i))

- URI <http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690>

+ [Details](#)

**Name:** usgaap\_ClassOfWarrantOrRightOutstanding

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:sharesItemType

**Balance Type:** na

**Period Type:** instant

X

- [References](#)

No definition available.

+ [Details](#)

**Name:** usgaap\_TextBlockAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

v3.4.0.3

| 10. Related Party Transactions (Details) - USD (\$)                     | 3 Months Ended |               |
|---|----------------|---------------|
|   | Mar. 31, 2016  | Mar. 31, 2015 |
| <a href="#">Details</a>   |                |               |
| <a href="#">Increase (Decrease) in Due to Officers and Stockholders</a> | \$ 43,680      | \$ 60,427     |

X

- Definition

The increase (decrease), during an accounting period, in total obligations owed to the reporting entity's executives and owners.

+ References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 230

- SubTopic 10

- Section 45

- Paragraph 28

- Subparagraph (a)

- URI <http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585>

+ Details

**Name:** us- gaap\_IncreaseDecreaseInDueToOfficersAndStockholders

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** debit

**Period Type:** duration

X

- References

No definition available.

+ Details

**Name:** usgaap\_TextBlockAbstract

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:stringItemType

**Balance Type:** na

**Period Type:** duration

| 11. Commitments (Details) - USD (\$)                          | 3 Months Ended |               | 12 Months Ended |               | Sep. 14, 2014 |
|---|----------------|---------------|-----------------|---------------|---------------|
|   | Mar. 31, 2016  | Mar. 31, 2015 | Jul. 05, 2015   | Dec. 31, 2014 |               |
| <a href="#">Oil and Gas Property, Lease Operating Expense</a> | \$ 16,530      |               |                 |               |               |
| <a href="#">CardioComm</a>                                    |                |               |                 |               |               |
| <a href="#">Amortization of Advance Royalty</a>               |                |               |                 | \$ 224,775    |               |
| <a href="#">Other Commitment</a>                              |                |               |                 |               | \$ 584,415    |
| <a href="#">Other Research and Development Expense</a>        | \$ 65,520      | \$ 72,513     |                 |               |               |
| <a href="#">iMedical</a>                                      |                |               |                 |               |               |
| <a href="#">Oil and Gas Property, Lease Operating Expense</a> |                |               | \$ 3,910        |               |               |
| <a href="#">Consulting services</a>                           |                |               | \$ 1,173        |               |               |

X

**- Definition**

The expense charged against earnings for the periodic recognition of the advance royalties. These royalties are paid in one accounting period, but are deducted from earnings over time through amortization. For example, royalties that are required to be paid in advance of production from a mineral, oil, or gas property and amortized over the period of right to produce these items.

**+ References**

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 230
- SubTopic 10
- Section 45
- Paragraph 28
- Subparagraph (b)
- URI <http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 225
- SubTopic 10
- Section S99
- Paragraph 2
- Subparagraph (SX 210.5- 03.3)
- URI <http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688>

**+ Details**

**Name:** us- gaap\_ AmortizationOfAdvanceRoyalty

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** debit

**Period Type:** duration

## X

### - Definition

Amount of lease operating expense related to property used in oil and gas production.

### + References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 840
- SubTopic 20
- Section 50
- Paragraph 1
- URI <http://asc.fasb.org/extlink&oid=6453985&loc=d3e41499-112717>

Reference 2: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher SEC
- Name Regulation S- X (SX)
- Number 210
- Section 10
- Paragraph a
- Subparagraph 17
- Article 4

### + Details

**Name:** us- gaap\_LeaseOperatingExpense

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** debit

**Period Type:** duration

## X

### - Definition

Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long- term and short- term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.

### + References

No definition available.

### + Details

**Name:** us- gaap\_OtherCommitment

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** credit

**Period Type:** instant

## X

### - Definition

Amount of general expenses not normally included in Other Operating Costs and Expenses.

### + References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB
- Name Accounting Standards Codification
- Topic 225
- SubTopic 10
- Section S99

- Paragraph 2
- Subparagraph (SX 210.5- 03.6)
- URI [http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235- 122688](http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688)

[+ Details](#)

**Name:** us- gaap\_OtherGeneralExpense

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** debit

**Period Type:** duration

X

[- Definition](#)

Amount of other research and development expense.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef>

- Publisher FASB

- Name Accounting Standards Codification

- Topic 730

- SubTopic 10

- Section 50

- Paragraph 1

- URI [http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568- 108373](http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373)

[+ Details](#)

**Name:** usgaap\_OtherResearchAndDevelopmentExpense

**Namespace Prefix:** us- gaap\_

**Data Type:** xbrli:monetaryItemType

**Balance Type:** debit

**Period Type:** duration

X

[- Details](#)

**Name:** fil\_CommitmentsAxis=fil\_CardiocommMember

**Namespace Prefix:**

**Data Type:** na

**Balance Type:**

**Period Type:**

X

[- Details](#)

**Name:** fil\_CommitmentsAxis=fil\_ImedicalMember

**Namespace Prefix:**

**Data Type:** na

**Balance Type:**

**Period Type:**

# Filing Summary

|                           |         |
|---------------------------|---------|
| <b>Version:</b>           | 3.4.0.3 |
| <b>ProcessingTime:</b>    |         |
| <b>ReportFormat:</b>      | html    |
| <b>ContextCount:</b>      | 18      |
| <b>ElementCount:</b>      | 129     |
| <b>EntityCount:</b>       | 1       |
| <b>FootnotesReported:</b> | true    |
| <b>SegmentCount:</b>      | 6       |
| <b>ScenarioCount:</b>     | 0       |
| <b>TuplesReported:</b>    | false   |
| <b>UnitCount:</b>         | 4       |

| IsDefault | HasEmbeddedReports | Html File Name | Long Name  | Report Type | Role  | Short Name  | Menu Category | ParentRole | Position |
|-----------|--------------------|----------------|--|-------------|---|---|---------------|------------|----------|
| false     | false              | R1.htm         | 000010 - Document - Document and Entity Information  | Sheet       | <a href="http://www.biotricity.com/20160331/role/idr_DocumentAndEntityInformation">http://www.biotricity.com/20160331/role/idr_DocumentAndEntityInformation</a>   | Document and Entity Information   | Cover         |            | 1        |
| false     | false              | R2.htm         | 000020 - Statement - Biotricity, Inc. - Condensed Consolidated Balance Sheets                                  | Sheet       | <a href="http://www.biotricity.com/20160331/role/idr_BiotricityIncCondensedConsolidatedBalanceSheets">http://www.biotricity.com/20160331/role/idr_BiotricityIncCondensedConsolidatedBalanceSheets</a>   | Biotricity, Inc. - Condensed Consolidated Balance Sheets                                  | Statements    |            | 2        |
| false     | false              | R3.htm         | 000030 - Statement - Statement of Financial Position - Parenthetical   | Sheet       | <a href="http://www.biotricity.com/20160331/role/idr_StatementOfFinancialPositionParenthetical">http://www.biotricity.com/20160331/role/idr_StatementOfFinancialPositionParenthetical</a>   | Statement of Financial Position - Parenthetical   | Statements    |            | 3        |
| false     | false              | R4.htm         | 000040 - Statement - Biotricity, Inc. - Condensed Consolidated Statements of Operations and Comprehensive Loss | Sheet       | <a href="http://www.biotricity.com/20160331/role/idr_BiotricityIncCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">http://www.biotricity.com/20160331/role/idr_BiotricityIncCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss</a> | Biotricity, Inc. - Condensed Consolidated Statements of Operations and Comprehensive Loss | Statements    |            | 4        |
| false     | false              | R5.htm         | 000050 - Statement - Biotricity, Inc. - Condensed Consolidated Statements of Cash Flows                        | Sheet       | <a href="http://www.biotricity.com/20160331/role/idr_BiotricityIncCondensedConsolidatedStatementsOfCashFlows">http://www.biotricity.com/20160331/role/idr_BiotricityIncCondensedConsolidatedStatementsOfCashFlows</a>   | Biotricity, Inc. - Condensed Consolidated Statements of Cash Flows                        | Statements    |            | 5        |
| false     | false              | R6.htm         | 000060 - Disclosure - 1. Nature of Operations  | Sheet       | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure1NatureOfOperations">http://www.biotricity.com/20160331/role/idr_Disclosure1NatureOfOperations</a>   | 1. Nature of Operations   | Notes         |            | 6        |
| false     | false              | R7.htm         | 000070 -   | Sheet       | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure2BasisOf">http://www.biotricity.com/20160331/role/idr_Disclosure2BasisOf</a>   | 2. Basis of   | Notes         |            | 7        |

|       |       |         |  |       |   |  |          |   |    |
|-------|-------|---------|--|-------|---|--|----------|---|----|
|       |       |         | Disclosure - 2. Basis of Presentation and Measurement  |       | 160331/role/idr_Disclosure2BasisOfPresentationAndMeasurement  | Presentation and Measurement   |          |   |    |
| false | false | R8.htm  | 000080 - Disclosure - 3. Going Concern   | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure3GoingConcern">http://www.biotricity.com/20160331/role/idr_Disclosure3GoingConcern</a>   | 3. Going Concern   | Notes    |   | 8  |
| false | false | R9.htm  | 000090 - Disclosure - 4. Summary of Significant Accounting Policies                              | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure4SummaryOfSignificantAccountingPolicies">http://www.biotricity.com/20160331/role/idr_Disclosure4SummaryOfSignificantAccountingPolicies</a>   | 4. Summary of Significant Accounting Policies                              | Notes    |   | 9  |
| false | false | R10.htm | 000100 - Disclosure - 5. Due To Shareholders   | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure5DueToShareholders">http://www.biotricity.com/20160331/role/idr_Disclosure5DueToShareholders</a>   | 5. Due To Shareholders   | Notes    |   | 10 |
| false | false | R11.htm | 000110 - Disclosure - 6. Accounts Payable and Accrued Liabilities                                | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure6AccountsPayableAndAccruedLiabilities">http://www.biotricity.com/20160331/role/idr_Disclosure6AccountsPayableAndAccruedLiabilities</a>   | 6. Accounts Payable and Accrued Liabilities                                | Notes    |   | 11 |
| false | false | R12.htm | 000120 - Disclosure - 7. Convertible Promissory Notes  | Notes | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure7ConvertiblePromissoryNotes">http://www.biotricity.com/20160331/role/idr_Disclosure7ConvertiblePromissoryNotes</a>   | 7. Convertible Promissory Notes  | Notes    |   | 12 |
| false | false | R13.htm | 000130 - Disclosure - 8. Derivative Liabilities  | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure8DerivativeLiabilities">http://www.biotricity.com/20160331/role/idr_Disclosure8DerivativeLiabilities</a>   | 8. Derivative Liabilities  | Notes    |   | 13 |
| false | false | R14.htm | 000140 - Disclosure - 9. Stockholders' Deficiency  | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure9StockholdersDeficiency">http://www.biotricity.com/20160331/role/idr_Disclosure9StockholdersDeficiency</a>   | 9. Stockholders' Deficiency  | Notes    |   | 14 |
| false | false | R15.htm | 000150 - Disclosure - 10. Related Party Transactions   | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure10RelatedPartyTransactions">http://www.biotricity.com/20160331/role/idr_Disclosure10RelatedPartyTransactions</a>   | 10. Related Party Transactions   | Notes    |   | 15 |
| false | false | R16.htm | 000160 - Disclosure - 11. Commitments  | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure11Commitments">http://www.biotricity.com/20160331/role/idr_Disclosure11Commitments</a>   | 11. Commitments  | Notes    |   | 16 |
| false | false | R17.htm | 000170 - Disclosure - 12. Subsequent Events  | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure12SubsequentEvents">http://www.biotricity.com/20160331/role/idr_Disclosure12SubsequentEvents</a>   | 12. Subsequent Events  | Notes    |   | 17 |
| false | false | R18.htm | 000180 - Disclosure - 4. Summary of Significant Accounting Policies: Use of Estimates (Policies) | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure4SummaryOfSignificantAccountingPoliciesUseOfEstimatesPolicies">http://www.biotricity.com/20160331/role/idr_Disclosure4SummaryOfSignificantAccountingPoliciesUseOfEstimatesPolicies</a> | 4. Summary of Significant Accounting Policies: Use of Estimates (Policies) | Policies | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure4SummaryOfSignificantAccountingPolicies">http://www.biotricity.com/20160331/role/idr_Disclosure4SummaryOfSignificantAccountingPolicies</a>                           | 18 |
| false | false | R19.htm | 000190 - Disclosure - 4. Summary of Significant Accounting Policies: Earnings                    | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure4SummaryOfSignificantAccountingPoliciesEarningsLossP">http://www.biotricity.com/20160331/role/idr_Disclosure4SummaryOfSignificantAccountingPoliciesEarningsLossP</a>                   | 4. Summary of Significant Accounting Policies: Earnings                    | Policies | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure4SummaryOfSignificantAccountingPoliciesEarningsLossP">http://www.biotricity.com/20160331/role/idr_Disclosure4SummaryOfSignificantAccountingPoliciesEarningsLossP</a> | 19 |

|       |       |         |  |       |   |  |          |   |    |
|-------|-------|---------|--|-------|---|--|----------|---|----|
|       |       |         | Accounting Policies: Earnings (loss) Per Share (Policies)  |       | erSharePolicies   | (loss) Per Share (Policies)  |          | ngPolicies  |    |
| false | false | R20.htm | 000200 - Disclosure - 4. Summary of Significant Accounting Policies: Fair Value of Financial Instruments (Policies)              | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure4SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsPolicies">http://www.biotricity.com/20160331/role/idr_Disclosure4SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsPolicies</a>                       | 4. Summary of Significant Accounting Policies: Fair Value of Financial Instruments (Policies)              | Policies | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure4SummaryOfSignificantAccountingPolicies">http://www.biotricity.com/20160331/role/idr_Disclosure4SummaryOfSignificantAccountingPolicies</a> | 20 |
| false | false | R21.htm | 000210 - Disclosure - 4. Summary of Significant Accounting Policies: Recently Issued Accounting Pronouncements (Policies)        | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure4SummaryOfSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsPolicies">http://www.biotricity.com/20160331/role/idr_Disclosure4SummaryOfSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsPolicies</a>         | 4. Summary of Significant Accounting Policies: Recently Issued Accounting Pronouncements (Policies)        | Policies | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure4SummaryOfSignificantAccountingPolicies">http://www.biotricity.com/20160331/role/idr_Disclosure4SummaryOfSignificantAccountingPolicies</a> | 21 |
| false | false | R22.htm | 000220 - Disclosure - 6. Accounts Payable and Accrued Liabilities: Schedule of Accounts Payable and Accrued Liabilities (Tables) | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure6AccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesTables">http://www.biotricity.com/20160331/role/idr_Disclosure6AccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesTables</a> | 6. Accounts Payable and Accrued Liabilities: Schedule of Accounts Payable and Accrued Liabilities (Tables) | Tables   |   | 22 |
| false | false | R23.htm | 000230 - Disclosure - 7. Convertible Promissory Notes: Convertible Debt (Tables)   | Notes | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure7ConvertiblePromissoryNotesConvertibleDebtTables">http://www.biotricity.com/20160331/role/idr_Disclosure7ConvertiblePromissoryNotesConvertibleDebtTables</a>   | 7. Convertible Promissory Notes: Convertible Debt (Tables)   | Tables   |   | 23 |
| false | false | R24.htm | 000240 - Disclosure - 7. Convertible Promissory Notes: Convertible Debt Table Text Block (Tables)                                | Notes | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure7ConvertiblePromissoryNotesConvertibleDebtTableTextBlockTables">http://www.biotricity.com/20160331/role/idr_Disclosure7ConvertiblePromissoryNotesConvertibleDebtTableTextBlockTables</a>   | 7. Convertible Promissory Notes: Convertible Debt Table Text Block (Tables)                                | Tables   |   | 24 |
| false | false | R25.htm | 000250 - Disclosure - 8. Derivative Liabilities: Schedule of Derivative Assets at Fair Value (Tables)                            | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure8DerivativeLiabilitiesScheduleOfDerivativeAssetsAtFairValueTables">http://www.biotricity.com/20160331/role/idr_Disclosure8DerivativeLiabilitiesScheduleOfDerivativeAssetsAtFairValueTables</a>   | 8. Derivative Liabilities: Schedule of Derivative Assets at Fair Value (Tables)                            | Tables   |   | 25 |
| false | false | R26.htm | 000260 - Disclosure - 8. Derivative  | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure8DerivativeLiabilitiesSchedule">http://www.biotricity.com/20160331/role/idr_Disclosure8DerivativeLiabilitiesSchedule</a>   | 8. Derivative Liabilities: Schedule of   | Tables   |   | 26 |



|       |       |         |   |       |   |   |         |   |    |
|-------|-------|---------|---|-------|---|---|---------|---|----|
|       |       |         | Liabilities: Schedule of Derivative Liabilities at Fair Value (Tables)  |       | eOfDerivativeLiabilitiesAtFairValueTables   | Derivative Liabilities at Fair Value (Tables)   |         |   |    |
| false | false | R27.htm | 000270 - Disclosure - 8. Derivative Liabilities: Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Tables) | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure8DerivativeLiabilitiesScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTables">http://www.biotricity.com/20160331/role/idr_Disclosure8DerivativeLiabilitiesScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTables</a> | 8. Derivative Liabilities: Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Tables) | Tables  |   | 27 |
| false | false | R28.htm | 000280 - Disclosure - 9. Stockholders' Deficiency: Schedule of Share-based Compensation, Activity (Tables)                            | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure9StockholdersDeficiencyScheduleOfShareBasedCompensationActivityTables">http://www.biotricity.com/20160331/role/idr_Disclosure9StockholdersDeficiencyScheduleOfShareBasedCompensationActivityTables</a>   | 9. Stockholders' Deficiency: Schedule of Share-based Compensation, Activity (Tables)                            | Tables  |   | 28 |
| false | false | R29.htm | 000290 - Disclosure - 9. Stockholders' Deficiency: Schedule of Stockholders' Equity Note, Warrants or Rights (Tables)                 | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure9StockholdersDeficiencyScheduleOfStockholdersEquityNoteWarrantsOrRightsTables">http://www.biotricity.com/20160331/role/idr_Disclosure9StockholdersDeficiencyScheduleOfStockholdersEquityNoteWarrantsOrRightsTables</a>                               | 9. Stockholders' Deficiency: Schedule of Stockholders' Equity Note, Warrants or Rights (Tables)                 | Tables  |   | 29 |
| false | false | R30.htm | 000300 - Disclosure - 3. Going Concern (Details)  | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure3GoingConcernDetails">http://www.biotricity.com/20160331/role/idr_Disclosure3GoingConcernDetails</a>   | 3. Going Concern (Details)  | Details | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure3GoingConcern">http://www.biotricity.com/20160331/role/idr_Disclosure3GoingConcern</a>   | 30 |
| false | false | R31.htm | 000310 - Disclosure - 6. Accounts Payable and Accrued Liabilities: Schedule of Accounts Payable and Accrued Liabilities (Details)     | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure6AccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails">http://www.biotricity.com/20160331/role/idr_Disclosure6AccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails</a>     | 6. Accounts Payable and Accrued Liabilities: Schedule of Accounts Payable and Accrued Liabilities (Details)     | Details | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure6AccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesTables">http://www.biotricity.com/20160331/role/idr_Disclosure6AccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesTables</a> | 31 |
| false | false | R32.htm | 000320 - Disclosure - 7. Convertible Promissory Notes: Convertible Debt (Details)   | Notes | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure7ConvertiblePromissoryNotesConvertibleDebtDetails">http://www.biotricity.com/20160331/role/idr_Disclosure7ConvertiblePromissoryNotesConvertibleDebtDetails</a>   | 7. Convertible Promissory Notes: Convertible Debt (Details)   | Details | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure7ConvertiblePromissoryNotesConvertibleDebtTables">http://www.biotricity.com/20160331/role/idr_Disclosure7ConvertiblePromissoryNotesConvertibleDebtTables</a>   | 32 |
| false | false | R33.htm | 000330 - Disclosure - 7. Convertible  | Notes | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure7ConvertiblePromissoryNotesConvertibleDebtTableTextBl">http://www.biotricity.com/20160331/role/idr_Disclosure7ConvertiblePromissoryNotesConvertibleDebtTableTextBl</a>   | 7. Convertible Promissory Notes: Convertible Debt   | Details | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure7ConvertiblePromissoryNotesC">http://www.biotricity.com/20160331/role/idr_Disclosure7ConvertiblePromissoryNotesC</a>   | 33 |

|       |       |         |  |       |   |  |         |   |    |
|-------|-------|---------|--|-------|---|--|---------|---|----|
|       |       |         | Promissory Notes: Convertible Debt Table Text Block (Details)  |       | ockDetails  | Table Text Block (Details)   |         | onvertibleDebtTableTextBlockTables  |    |
| false | false | R34.htm | 000340 - Disclosure - 8. Derivative Liabilities: Schedule of Derivative Assets at Fair Value (Details)                                 | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure8DerivativeLiabilitiesScheduleOfDerivativeAssetsAtFairValueDetails">http://www.biotricity.com/20160331/role/idr_Disclosure8DerivativeLiabilitiesScheduleOfDerivativeAssetsAtFairValueDetails</a>   | 8. Derivative Liabilities: Schedule of Derivative Assets at Fair Value (Details)                                 | Details | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure8DerivativeLiabilitiesScheduleOfDerivativeAssetsAtFairValueTables">http://www.biotricity.com/20160331/role/idr_Disclosure8DerivativeLiabilitiesScheduleOfDerivativeAssetsAtFairValueTables</a>   | 34 |
| false | false | R35.htm | 000350 - Disclosure - 8. Derivative Liabilities: Schedule of Derivative Liabilities at Fair Value (Details)                            | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure8DerivativeLiabilitiesScheduleOfDerivativeLiabilitiesAtFairValueDetails">http://www.biotricity.com/20160331/role/idr_Disclosure8DerivativeLiabilitiesScheduleOfDerivativeLiabilitiesAtFairValueDetails</a>   | 8. Derivative Liabilities: Schedule of Derivative Liabilities at Fair Value (Details)                            | Details | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure8DerivativeLiabilitiesScheduleOfDerivativeLiabilitiesAtFairValueTables">http://www.biotricity.com/20160331/role/idr_Disclosure8DerivativeLiabilitiesScheduleOfDerivativeLiabilitiesAtFairValueTables</a>   | 35 |
| false | false | R36.htm | 000360 - Disclosure - 8. Derivative Liabilities: Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure8DerivativeLiabilitiesScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails">http://www.biotricity.com/20160331/role/idr_Disclosure8DerivativeLiabilitiesScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails</a> | 8. Derivative Liabilities: Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) | Details | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure8DerivativeLiabilitiesScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTables">http://www.biotricity.com/20160331/role/idr_Disclosure8DerivativeLiabilitiesScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTables</a> | 36 |
| false | false | R37.htm | 000370 - Disclosure - 9. Stockholders' Deficiency (Details)  | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure9StockholdersDeficiencyDetails">http://www.biotricity.com/20160331/role/idr_Disclosure9StockholdersDeficiencyDetails</a>   | 9. Stockholders' Deficiency (Details)  | Details | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure9StockholdersDeficiencyScheduleOfShareBasedCompensationActivityTables">http://www.biotricity.com/20160331/role/idr_Disclosure9StockholdersDeficiencyScheduleOfShareBasedCompensationActivityTables</a>   | 37 |
| false | false | R38.htm | 000380 - Disclosure - 9. Stockholders' Deficiency: Schedule of Share-based Compensation, Activity (Details)                            | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure9StockholdersDeficiencyScheduleOfShareBasedCompensationActivityDetails">http://www.biotricity.com/20160331/role/idr_Disclosure9StockholdersDeficiencyScheduleOfShareBasedCompensationActivityDetails</a>   | 9. Stockholders' Deficiency: Schedule of Share-based Compensation, Activity (Details)                            | Details | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure9StockholdersDeficiencyScheduleOfShareBasedCompensationActivityTables">http://www.biotricity.com/20160331/role/idr_Disclosure9StockholdersDeficiencyScheduleOfShareBasedCompensationActivityTables</a>   | 38 |
| false | false | R39.htm | 000390 - Disclosure - 9. Stockholders' Deficiency: Schedule of Stockholders' Equity Note, Warrants or Rights (Details)                 | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure9StockholdersDeficiencyScheduleOfStockholdersEquityNoteWarrantsOrRightsDetails">http://www.biotricity.com/20160331/role/idr_Disclosure9StockholdersDeficiencyScheduleOfStockholdersEquityNoteWarrantsOrRightsDetails</a>                               | 9. Stockholders' Deficiency: Schedule of Stockholders' Equity Note, Warrants or Rights (Details)                 | Details | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure9StockholdersDeficiencyScheduleOfStockholdersEquityNoteWarrantsOrRightsTables">http://www.biotricity.com/20160331/role/idr_Disclosure9StockholdersDeficiencyScheduleOfStockholdersEquityNoteWarrantsOrRightsTables</a>                               | 39 |
| false | false | R40.htm | 000400 - Disclosure - 10. Related Party Transactions   | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure10RelatedPartyTransactionsDetails">http://www.biotricity.com/20160331/role/idr_Disclosure10RelatedPartyTransactionsDetails</a>   | 10. Related Party Transactions (Details)   | Details | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure10RelatedPartyTransactions">http://www.biotricity.com/20160331/role/idr_Disclosure10RelatedPartyTransactions</a>   | 40 |

|       |       |         |   |       |   |                           |         |   |    |
|-------|-------|---------|---|-------|---|---------------------------|---------|---|----|
|       |       |         | (Details)                                       |       |   |                           |         |   |    |
| false | false | R41.htm | 000410 - Disclosure - 11. Commitments (Details) | Sheet | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure11CommitmentsDetails">http://www.biotricity.com/20160331/role/idr_Disclosure11CommitmentsDetails</a> | 11. Commitments (Details) | Details | <a href="http://www.biotricity.com/20160331/role/idr_Disclosure11Commitments">http://www.biotricity.com/20160331/role/idr_Disclosure11Commitments</a> | 41 |
| false | false |         | All Reports                                     | Book  |   | All Reports               |         |   |    |

### Input Files

btcy-20160331.xml

btcy-20160331.xsd

btcy-20160331\_cal.xml

btcy-20160331\_def.xml

btcy-20160331\_lab.xml

btcy-20160331\_pre.xml

**HasPresentationLinkbase:** true

**HasPresentationLinkbase:** true